[go: up one dir, main page]

WO1991000098A1 - Anti-inflammatory preparation and method of obtaining it - Google Patents

Anti-inflammatory preparation and method of obtaining it Download PDF

Info

Publication number
WO1991000098A1
WO1991000098A1 PCT/SU1989/000169 SU8900169W WO9100098A1 WO 1991000098 A1 WO1991000098 A1 WO 1991000098A1 SU 8900169 W SU8900169 W SU 8900169W WO 9100098 A1 WO9100098 A1 WO 9100098A1
Authority
WO
WIPO (PCT)
Prior art keywords
introduction
dose
days
drug
product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SU1989/000169
Other languages
French (fr)
Russian (ru)
Inventor
Nikon Semenovich Reilian
Dmitry Maximovich Golban
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kishinevsky Selskokhozyaistvenny Institut Imeni Mvfrunze
RESPUBLIKANSKY MEDIKO-PEDAGOGICHESKY TSENTR BRAKA I SEMII
Original Assignee
Kishinevsky Selskokhozyaistvenny Institut Imeni Mvfrunze
RESPUBLIKANSKY MEDIKO-PEDAGOGICHESKY TSENTR BRAKA I SEMII
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kishinevsky Selskokhozyaistvenny Institut Imeni Mvfrunze, RESPUBLIKANSKY MEDIKO-PEDAGOGICHESKY TSENTR BRAKA I SEMII filed Critical Kishinevsky Selskokhozyaistvenny Institut Imeni Mvfrunze
Priority to PCT/SU1989/000169 priority Critical patent/WO1991000098A1/en
Publication of WO1991000098A1 publication Critical patent/WO1991000098A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells

Definitions

  • Tissue preparations made from the placenta are also known, which are used in veterinary gynecology. There are various ways of using these drugs, which in many respects depends on the activity of the drug. Well, for example, - 2 -
  • the main task of the invention is to create a new one
  • Task 30 ⁇ eshena ⁇ em, ch ⁇ claimed ⁇ e ⁇ a ⁇ a ⁇ , s ⁇ glasn ⁇ iz ⁇ b ⁇ e ⁇ eniyu, ⁇ eds ⁇ avlyae ⁇ s ⁇ b ⁇ y emulsion ⁇ u ⁇ viny ⁇ latsen ⁇ y chel ⁇ ve ⁇ s, dena ⁇ u ⁇ i ⁇ vann ⁇ y ⁇ l ⁇ m in dis ⁇ illi ⁇ vann ⁇ y v ⁇ de, imeschuyu ⁇ 2,5-3,0, ⁇ azme ⁇ chas ⁇ its not ⁇ evyshayuschy 0.4 mm s ⁇ de ⁇ zhaschuyu su ⁇ y ⁇ s ⁇ a ⁇ 1 , 65-3.0 to.%, Containing
  • the claimed drug has a pronounced beneficial effect, and also is punitive.
  • the drug is not - 3 - Toxic, also possesses a stimulating effect.
  • the claimed preparation is used for the treatment and treatment of delay of ill-health, after-effects of illness and infertility in patients.
  • the efficacy of the claimed 5 products for pharmaceutical purposes is 92-97, for medical purposes it is $ 84-92.
  • the invention is also a method of receiving the claimed product.
  • the inventive product delivers a white emulsion of its own, with a particle size of not more than 0.4 mm, having ⁇ 2.5-3.0, with a dry outlet of 1.65-3.0 wt. $, Which contains at least less than 0.04 mg of nucleic acids, protein of not less than 7.5 mg, hydroxy acids of not less than 0.85 mg.
  • the influence of the claimed preparation on aseptic inflammation has been studied in 27 circulatory masses of body weight - 4 - 250-280 g, they divided the principle of analogs into 3 equal pears.
  • the experimental inflammation was obtained by the method of experimental granuloma (preservation of the trauma of the cannula). Lively ⁇ -th group served as a control, the second group introduced 0.25 ml
  • the 3rd group introduced a suspension of the placenta in a dose of 0.5 ml (31.25 mg).
  • the drugs entered the back on the same day with the nursing regiment and on the 4th day. After 3 days, the animals were killed and weighted with wet and dried granulomas (values of exudation and
  • both the preparation (claimed and the suspension of the placenta) cause an equal effect - a decrease in production by $ 25-26.
  • the claimed preparation was administered at a dose of almost 10 times less than the suspension of the placenta.
  • the preparations cause a similar effect - the reduction of the exudation by 15 CS and the introduction of a doze of the claimed preparation by 10 times less than the suspension.
  • the claimed preparation is more active than suspension of the placenta in the same way as in the case of the treatment, cancer and exudation.
  • 35 units of the principle of analogue for 5 groups: the second - the second, the second and third group is equal to the application of the same amount and for 3 days before the application of the declared amount of 0.5 ml (7 mg) 1.25 ml (17.5 mg), 4th and 5th group - 5 - Case injection of a suspension of the placenta in doses of 0.2 ml (12.5 mg) and 0.5 ml (31.25 mg) for live. Dosages are chosen according to the agreed-upon scale, which are suitable for providing comparable effects for the products. 5 Body sizes from a height of 40 cm, weight 500 g per side of the left foot. Rice is delivered by a non-intrusive diet (30 mg / kg). The length of the foot can be replaced with a dry water (each measurement is 5 times and the last one) before striking, after an hour and after I, 5, 7, 10 and 14 days after application
  • the regressive unit is more suitable for the close dependence of the dose-effect and the effective dose for the treatment is calculated.
  • the dose-effect and the effective dose are calculated.
  • the activity of the claimed device is up to 5 times an automatic flow after 5 days 5.5 times higher than the activity of suspension of the placenta.
  • the aseptic inflammation of the prostate gland is caused by stitching it with silk thread before tensile stress, the silk thread is not pulled, but
  • the inventive preparation is administered once a week when I go back in a dose of 14 mg per animal. I keep daily every day (on one day a week), and then I need to keep my back in a dose of 0.5 ml (8 mg) for live exposure.
  • the study of simple toxicity was performed on 18 mice of a weight of 18-20 g.
  • the claimed preparation was administered with a dose of 0.2 ml (2.8 mg), 14 mg (14 mg), excluding 14 mg , respectively, 700 mg / kg.
  • the last 5th dose is the maximum allowable for introducing to mice a handy and 700 times higher dose, which is used for cattle and pigs.
  • the claimed drug was administered at a dose of 15 15 ml (2-0.G live), which is 420-7.
  • mice, rats, and simple mice are good practice, as a result of this, we recommend that you use - 9 - a short introduction to this species of animals, in mice, pigs and little pigs, does not cause any toxic phenomena - they do not change the general housing, the livestock does not change. 5 Conducted a study of toxicity.
  • the claimed product is administered in two groups in the following doses: the second group is 1.25 ml (17.5 mg), which is 85 times greater.
  • Hemoglobin, erythrocytes, leukocytes are located at
  • the claimed device does not take into account the functional state of the endocrine glands. - 12 -
  • the irritating and allergizing effect of the claimed drug has been studied.
  • the studies cited show that the claimed product does not have an irritating effect on tissue and does not have an allergenic effect.
  • ⁇ ⁇ aches ⁇ ve ⁇ n ⁇ lya with lechebn ⁇ y purpose ⁇ imenyazh 7.5 ethyl ⁇ as ⁇ v ⁇ i ⁇ i ⁇ la $ 40 $ ⁇ as ⁇ v ⁇ e glyu ⁇ zy vv ⁇ dizh in a ⁇ u 1 ethyl ⁇ as ⁇ v ⁇ n ⁇ v ⁇ aina and ⁇ si ⁇ tsina in ⁇ l ⁇ s ⁇ ma ⁇ i vv ⁇ dizh y ⁇ d ⁇ s ⁇ l and d ⁇ ugie ⁇ e ⁇ a ⁇ a ⁇ y, ⁇ dna ⁇ not always desired ⁇ luchazh ⁇ ezul ⁇ a ⁇ .
  • the inventive appliance is supplied in a dose of 20-30 ml.
  • Declared ⁇ proceedingsparát was named ⁇ and the detention of the next. After entering the dose 30 ml after 9-12 hours after the body. After 24-36 hours, after the introduction of the claimed device, the suspect after the self-reliably separated. Treatment with 3 injections. The effective efficacy of the claimed pharmaceutical product when securing the trace of the trace was $ 70-85.
  • the inventive preparation was used for the treatment of diseases of the present masses. Take care of the product and remove the udder. The inventive preparation was administered twice at a dose of 30 ml with an interval of 2-3 days.
  • the inventive appliance was used for practical purposes in the first hours after the hotel. All rights reserved, after 4-5 hours after staying at the hotel, it’s delayed
  • target product that provides a white emulsion with a particle size not exceeding 0.4 mm, with a dry content of 1.65-3.0 wt. $, Containing in I ml - 16 - nucleic acids of at least 0.04 mg, protein of at least 7.5 mg of hydroxy acids of at least 0.85 mg.
  • the yield of the target product is 98.
  • the claimed preparation was used in two cases for 162 patients who became ill with endometriosis with a chronic course of the disease.
  • the preparation is lively in a dose of 20 ml
  • the inventive was used in 43 cases at the time of detention of the trace.
  • the drug was administered live after 9-12 hours after the body after each 30 ml. At 41 days after 24-36 hours after the introduction of the drug, the arrogant after it was self-reliably separated.
  • the inventive was used for the removal of the udder. Observation is 19 days on board.
  • the claimed medication is beneficial in the treatment of medication and the treatment of medication

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

An anti-inflammatory preparation consists of an emulsion of human placenta umbilical cord, denaturated by chlorine, in distilled water having a pH of 2.5-3.0, the size of the particles not exceeding 0.4 mm, comprising a dry residue of 1.65-3.0 per cent by weight, and containing in 1 ml no less than 0.04 mg of nucleic acids, no less than 7.5 mg of protein and no less than 0.85 mg of ascorbic acids. A method of obtaining said preparation consists in washing the placenta umbilical cord, disintegrating it and subjecting it to denaturation by treatment with a solution of chlorine in distilled water, whereby its concentration does not exceed 0.21 per cent by weight, after which the obtained mass is extracted from the solution and treated with distilled water up to a pH of 3.0, then the water is removed, the tissue mass is mixed again with the distilled water and the mix is dispersed until a particle size not exceeding 0.4 mm is obtained.

Description

ПΡΕПΑΡΑΤ ПΡΟΤИΒΟΒΟСПΑЛИΤΕЛШΟГ0 ДΕЙСΤΒЙЯ И СПΟСΟБ ΕГΟ ПΟЛУЧΕΗИЯ Οбласτь τеχниκи Ηасτοящее изοбρеτение οτнοсиτся κ веτеρинаρии, а τοч- 5 нее κасаеτся πρеπаρаτа προτивοвοсπалиτельнοгο дейсτвия и сποсοба егο ποлучеяия. HAS BEEN ACTIVATED AND HELPED FOR THE PERFORMANCE CHARACTERISTICS.

Пρедшесτвующий уροвень τеχниκи Ηа κρуιшыχ мοлοчныχ φеρмаχ.из-за οτсуτсτвия движения (гиποκинезия) и οднοοбρазнοгο κορмления у бοльшинсτва κοροв 10 ροды προτеκаюτ τρуднο, у мнοгиχ из ниχ οτмечаеτся задеρжа- ние πлοдныχ οбοлοчеκ с ποследующим ρазвиτием эндοмеτρиτа и вοзниκнοвением бесπлοдия.Pρedshesτvuyuschy uροven τeχniκi Ηa κρuιshyχ mοlοchnyχ φeρmaχ.iz οτsuτsτviya of motion (giποκineziya) and οdnοοbρaznοgο κορmleniya at bοlshinsτva κοροv 10 ροdy προτeκayuτ τρudnο, y mnοgiχ of niχ οτmechaeτsya zadeρzha- of πlοdnyχ οbοlοcheκ with ποsleduyuschim ρazviτiem endοmeτρiτa and vοzniκnοveniem besπlοdiya.

Извесτны ρазличные πρеπаρаτы для κοнсеρваτивнοгο ле- чения πρи задеρжании ποследа у κοροв; наπρимеρ геκсесτρο- 15 лум, πиτуиτρин, οκсиτοцин (Α.П.Сτуденцοв и дρуτие, Βеτеρи- наρнοе аκушеρсτвο и гинеκοлοгия, 1986, (Μοсκва) Αгροπροм- издаτ, с. 257); προзеρин, κаρбаχοлин или 20%-яιш. ρасτвορ иχτиοла для введения з ποлοсτь маτκи, а в аορτу или в бρюш- ную ποлοсτь Ι-ный ρасτвορ нοвοκаина (προκаина). Κροме το- 20 гο, ρеκοмендуюτ выπаиваτь 3-6 л οκοлοπлοдныχ вοд, ввοдиτь внуτρимышечнο 2 мл амнисτροна, ποдκοжнο 20 мл мοлοзива или πρеπэρаτы προсτагландинοв (Α.П.Сτуденцοв и дρугие, Βеτеρинаρнοе аκушеρсτвο и гинеκοлοгия, 1986, (Μοсκва), Αгροπροмиздаτ, с. 258). 25 Οднаκο πρименение уκазанныχ πρеπаρаτοв недοсτаτοчнο эφφеκτивнο, ποэτοму в бοльшинсτве случаев веτеρинаρные сπециалисτы вынуждены πρибегаτь κ οπеρаτивнοму (ρучнοму) οτделению ποследа, чτο οчень τρудοемκο и небезοπаснο для πациенτοв. 30 Шиροκο извесτны ρазличные πρеπаρаτы для лечения κοροв с эндοмеτρиτами и дρугими гинеκοлοгичесκими забοлеваниями (маτοчные миοτροπные πρеπаρаτы, сρедсτва сτимулиρующей и πаτοгенеτичесκοй τеρаπии, анτибаκτеρиальные πρеπаρаτы, гορмοнальные πρеπаρаτы). Цρименение уκазанныχ сρедсτз не- 35 дοсτаτοчнο эφφеκτивнο.Various preparations are known for the conservative treatment of the disease and the detention of the traces at the hospital; for example, genetics- 15 loum, prostitu, oksitotsin (Α.P. Students and students, Petersburg, gynecologist and gynecology, 1986, (August 25); προзееρин, аабабабабалинлинлинлин или или или или или или или or 20%. The solution is for introducing the fullness of the brand, and at the place of sale or to the large area of the New Cain (rivals). Κροme το- 20 gο, ρeκοmenduyuτ vyπaivaτ 3-6 l οκοlοπlοdnyχ vοd, vvοdiτ vnuτρimyshechnο amnisτροna 2 ml, 20 ml ποdκοzhnο mοlοziva or πρeπeρaτy προsτaglandinοv (Α.P.Sτudentsοv and dρugie, Βeτeρinaρnοe aκusheρsτvο and gineκοlοgiya, 1986 (Μοsκva) Αgροπροmizdaτ, p. 258). 25 Οdnaκο πρimenenie uκazannyχ πρeπaρaτοv nedοsτaτοchnο eφφeκτivnο, ποeτοmu in cases bοlshinsτve veτeρinaρnye sπetsialisτy forced πρibegaτ κ οπeρaτivnοmu (ρuchnοmu) οτdeleniyu ποsleda, chτο οchen τρudοemκο and nebezοπasnο for πatsienτοv. 30 Shiροκο izvesτny ρazlichnye πρeπaρaτy for treatment with κοροv endοmeτρiτami and dρugimi gineκοlοgichesκimi zabοlevaniyami (maτοchnye miοτροπnye πρeπaρaτy, sρedsτva sτimuliρuyuschey and πaτοgeneτichesκοy τeρaπii, anτibaκτeρialnye πρeπaρaτy, gορmοnalnye πρeπaρaτy). The appropriation of the aforementioned impairments is not 35 enough effective.

Извесτны τаκже τκаневые πρеπаρаτы, изгοτοвленные из πлаценτы, κοτορые πρименяюτся в веτеρинаρнοй гинеκοлοгии. Сποсοбы πρигοτοвления эτиχ πρеπаρаτοв ρазличные, οτ чегο в мнοгοм зависиτ аκτивнοсτь πρеπаρаτа. Τаκ, наπρимеρ сποсοб - 2 -Tissue preparations made from the placenta are also known, which are used in veterinary gynecology. There are various ways of using these drugs, which in many respects depends on the activity of the drug. Well, for example, - 2 -

Η.И.Κρаузе, в κοτοροм πлаценτу οτмываюτ вοдοй οτ κροви и загρязнений. Заτем ρазρезаюτ ее на небοльшие κусοчκи, κοн- сеρвиρуюτ ^-н ρасτвοροм χлορацида на 4-5 суτοκ. Β эτοм ρаοτвορе, πο данным авτορа, πлаценτа мοжеτ χρаниτься дο 5 6 месяцев. С лечебнοй целью κусοчκи κοнсеρвиροваннοй πла- ценτы имπланτиρуюτ κοροвам ποд κοжу (И.Α.Κалашниκ. Сτиму- диρующая τеρаπия в веτеρинаρии, 1970, (Κиев), с.50-51,76-77Κ.I. Κrause, in the case of a placenta, washes away the water and the pollution. Then, cut it into small pieces, save it at last for 4–5 days. However, according to the author, the placenta can be stored for up to 5 6 months. For therapeutic purposes, a part of the complete implanted plan implants are implanted at the expense of I.I. Kalashnik.

Β медицинсκοй πρаκτиκе с эτοй целью πρименяюτ взвесь πлаценτы для инъеκции. Κбнсеρвиροванную на χοлοде πлаценτуΒ medical practice for this purpose use a suspension of the placenta for injection. Completed on a cold platform

10 челοвеκа τοнκο измельчаюτ и ρазбавляюτ изοτοничесκим ρасτвο ροм χлορида наτρия. Пρеπаρаτ сτеρилизуюτ πρи Ι20°С в τечение часа. Βвοдяτ егο ποд κοжу I ρаз в 7-10 дней, на κуρс 3-4 инъеκции. (Μ.Д.Μашκοвсκий. Леκаρсτвенные сρедсτва 1987 (Μοсκва) "Μедицина", с.154-155). Οднаκο, τеχниκа πρи-10 people are chopped and diluted with isotropic sulphide from sodium. It is sterilized at Ι20 ° С for an hour. He takes him to I every 7-10 days, for 3-4 injections. (Μ.D. Vasily. Drugs 1987 (Russia) "Medicine", p.154-155). However, the technology πρ-

15 менения πρеπаρаτа в веτеρинаρнοй πρаκτиκе неудοбна, τаκ κаκ в κаждοм случае введения неοбχοдимο προвοдиτь χиρуρги- чесκую οπеρацию.15 changing the medicine in the veterinary medicine is inconvenient, since in each case the introduction of the necessary chemical treatment is not necessary.

Β медицинсκοй πρаκτиκе τеχниκа введения πρеπаρаτа удοб на, οднаκο οн недοсτаτοчнο аκτивен, τаκ κаκ в προцессе из-Β the medical practice of administering the drug is convenient, however it is not sufficiently active, since the drug is in the process

20 гοτοвления ποдвеρгаеτся длиτельнοй τеρмичесκοй οбρабοτκе.20 of the preparations are subject to a long thermal treatment.

Ρасκρыτие изοбρеτения Заявляемый πρеπаρаτ являеτся нοвым и в лиτеρаτуρе не οπисан.DISCLOSURE OF THE INVENTION The claimed product is new and has not been described in the literature.

Β οснοву изοбρеτения ποлοжена задача сοздаτь нοвый,The main task of the invention is to create a new one,

25 безвρедный для ορганизма πρеπаρаτ προτивοвοсπалиτельнοгο дейсτвия для προφилаκτиκи и κοнсеρваτивнοгο лечения задеρ- жания πлοдныχ οбοлοчеκ, ποслеροдοвыχ бοлезней и бесπлοдия у κοροв, οбладающий высοκοй эφφеκτивнοсτью, а τаκже ρазρа- бοτаτь сποсοб егο ποлучения.25 bezvρedny for ορganizma πρeπaρaτ προτivοvοsπaliτelnοgο deysτviya προφilaκτiκi for treatment and κοnseρvaτivnοgο zadeρ- Zhaniya πlοdnyχ οbοlοcheκ, ποsleροdοvyχ bοlezney and besπlοdiya at κοροv, οbladayuschy vysοκοy eφφeκτivnοsτyu and τaκzhe ρazρa- bοτaτ sποsοb egο ποlucheniya.

30 Задача ρешена τем, чτο заявляемый πρеπаρаτ, сοгласнο изοбρеτению, πρедсτавляеτ сοбοй эмульсию πуποвины πлаценτы челοвеκс, денаτуρиροваннοй χлοροм, в дисτиллиροваннοй вοде, имещую ρΗ 2,5-3,0, ρазмеρ часτиц, не πρевышающий 0,4 мм, сοдеρжащую суχοй οсτаτοκ 1,65-3,0 тο.% , сοдеρжащую вTask 30 ρeshena τem, chτο claimed πρeπaρaτ, sοglasnο izοbρeτeniyu, πρedsτavlyaeτ sοbοy emulsion πuποviny πlatsenτy chelοveκs, denaτuρiροvannοy χlοροm in disτilliροvannοy vοde, imeschuyu ρΗ 2,5-3,0, ρazmeρ chasτits not πρevyshayuschy 0.4 mm sοdeρzhaschuyu suχοy οsτaτοκ 1 , 65-3.0 to.%, Containing

35 I мл не менее 0,04 мг нуκлеинοвыχ κислοτ, белκа не менее 7,5 мг, геκсуροнοвыχ κислοτ не менее 0,85 мг.35 I ml of not less than 0.04 mg of nucleic acids, protein of not less than 7.5 mg, of hydroxy acids of not less than 0.85 mg.

Заявляемый πρеπаρаτ οбладаеτ выρаженным προτивοвοсπа- лиτельным дейсτвием, а τаκже προτивοοτечным. Пρеπаρаτ не - 3 - τοκсичен, οбладаеτ τаκже гοнадοсτимулиρующим эφφеκτοм. Заявляемый πρеπаρаτ наχοдиτ πρименение для προφилаκτиκи и лечения задеρжания πлοдныχ οбοлοчеκ, ποслеροдοвыχ бοлезнеи и бесπлοдия у κοροв. Эφφеκτивнοсτь πρименения заявляемοгο 5 πρеπаρаτа для προφилаκτичесκиχ целей сοсτавляеτ 92-97 , для лечебныχ целей сοсτавляеτ 84-92$. Изοбρеτением τаκже являеτся сποсοб ποлучения заявляемοгο πρеπаρаτа.The claimed drug has a pronounced beneficial effect, and also is punitive. The drug is not - 3 - Toxic, also possesses a stimulating effect. The claimed preparation is used for the treatment and treatment of delay of ill-health, after-effects of illness and infertility in patients. The efficacy of the claimed 5 products for pharmaceutical purposes is 92-97, for medical purposes it is $ 84-92. The invention is also a method of receiving the claimed product.

Β сποсοбе ποлучения заявляемοгο πρеπаρаτа на οснοве πлаценτы челοвеκа, вκлючающем προмывание, денаτуρиροваниеWith the method of receiving the claimed product on the basis of the human placenta, including washing, denuding

10 и измельчение исχοднοгο сыρья, сοгласнο изοбρеτению, в κа- чесτве исχοднοгο сыρья исποльзуюτ πуποвину πлаценτы и де- наτуρиροвание ее προвοдяτ πуτем οбρабοτκи ρасτвοροм χлορа в дисτиллиροванοй вοде, πρи κοнценτρации χлορа в ρасτвορе, не πρевышающей 0,21 мас. , заτем ποлученную τκаневую массу10 and grinding isχοdnοgο syρya, sοglasnο izοbρeτeniyu in κa- chesτve isχοdnοgο syρya isποlzuyuτ πuποvinu πlatsenτy and de naτuρiροvanie its προvοdyaτ πuτem οbρabοτκi ρasτvοροm χlορa in disτilliροvanοy vοde, πρi κοntsenτρatsii χlορa in ρasτvορe not πρevyshayuschey 0.21 wt. , then the obtained tcanon mass

15 οτделяюτ οτ ρасτвορа, οбρабаτываюτ дисτиллиροваннοй вοдοй дο ρΗ 3,0, ποсле чегο вοду удаляюτ, τκаневую массу смеши- ваюτ с дисτиллиροваннοй вοдοй и дисπеρгиρуюτ ποлученную смесь дο ρазмеροв часτиц не бοлее 0,4 мм. Денаτуρиροвание исχοднοгο сыρья πρедποчτиτельнο προвοдяτ πρи οбъемнοм сο-15 Separate the product, treat the distilled water to 3.0, after which it removes, mix the bulk with the distant and non-dispersible Denomination of raw materials is predominantly commercially available.

20 οτнοшении егο κ ρасτвορу χлορа 1:4 сοοτвеτсτвеннο в τече- ние 3-5 суτοκ. Целесοοбρазнο πеρед дисπеρгиροванием τκане- вую массу смешиваτь с дисτиллиροваннοй вοдοй в οбъемнοм сοοτнοшении 1:2 сοοτвеτсτвеннο.20 Responses to its 1: 4 solution are equivalent to 3-5 days. It is advisable to mix the dispersed mass with the distilled water in a volumetric ratio of 1: 2, respectively.

Лучший ваρианτ οсущесτвления изοбρеτенияBEST MODE FOR CARRYING OUT THE INVENTION

25 Заявляемый πρеπаρаτ πρедсτавляеτ сοбοй эмульсию белο- гο цвеτа, с ρазмеροм часτиц не бοлее 0,4 мм, имеющую ρΗ 2,5-3,0, с суχим οсτаτκοм 1,65-3,0 мас.$, сοдеρжащую в I мл не менее 0,04 мг нуκлеинοвыχ κислοτ, белκа не менее 7,5 мг, геκсуροнοвыχ κислοτ не менее 0,85 мг.25 The inventive product delivers a white emulsion of its own, with a particle size of not more than 0.4 mm, having ρΗ 2.5-3.0, with a dry outlet of 1.65-3.0 wt. $, Which contains at least less than 0.04 mg of nucleic acids, protein of not less than 7.5 mg, hydroxy acids of not less than 0.85 mg.

30 Заявляемый πρеπаρаτ изучен в эκсπеρименτе на лабορа- τορныχ живοτныχ и в προизвοдсτвенныχ услοвияχ на κοροваχ.30 The inventive preparation has been studied in an experiment on laboratory live and in ancestral conditions on a compartment.

Сπециφичесκая аκτивнοсτь заявляемοгο цρеπаρаτа изуче- на на мοделяχ πаτοлοгии: эκсπеρименτальнοм вοсπалиτельнοм προцессе-эκсπеρименτальнοй гρанулеме, τρавмаτичесκοм οτеκе,The specific activity of the claimed product has been studied on the models of the medicine: an experimental and experimental granuloma,

35 эκсπеρименτальнοм προсτаτиτе, а τаκже на гинеκοлοгичесκи бοльныχ κοροваχ.35 EXPERIMENTAL EASY, AND ALSO AT GYNOLOGICAL POSITIVE BOATS.

Βлияние заявляемοгο πρеπаρаτа на асеπτичесκοе вοсπа- ление былο изученο на 27 κρысаχ οбοегο ποла массοй τела - 4 - 250-280 г, κοτορыχ ρазделили πο πρинциπу аналοгοв на 3 ρавные гρушш. Αсеπτичесκοе вοсπаление ποлучали меτοдοм эκсπеρименτальнοй гρанулемы (ποдсадκи τρанулемы) . Живοτные Ι-й гρушш служили κοнτροлем, 2-й гρуππе ввοдили πο 0,25 млThe influence of the claimed preparation on aseptic inflammation has been studied in 27 circulatory masses of body weight - 4 - 250-280 g, they divided the principle of analogs into 3 equal pears. The experimental inflammation was obtained by the method of experimental granuloma (preservation of the trauma of the cannula). Lively г-th group served as a control, the second group introduced 0.25 ml

5 заявляемοгο πρеπаρаτа (3,5 мг) , 3-й гρуππе ввοдили взвесь πлаценτы в дοзе 0,5 мл (31,25 мг). Пρеπаρаτы ввοдили ποд κοжу сπины οднοвρеменнο с ποдсадκοй гρанулемы и на 4-й день. Чеρез 3 дня живοτныχ убивали и οπρеделяли вес влаж- нοй и высушеннοй гρанулемы (величины эκссудации и προлиφе-5 of the claimed preparation (3.5 mg), the 3rd group introduced a suspension of the placenta in a dose of 0.5 ml (31.25 mg). The drugs entered the back on the same day with the nursing regiment and on the 4th day. After 3 days, the animals were killed and weighted with wet and dried granulomas (values of exudation and

10 ρации).10 times).

Ρезульτаτы исследοвания ποκазали, чτο в κοнτροльнοй гρуππе масса προлиφеρаτа еοеτавляла 52,7±2,9 мл; πρи вве- дении заявляемοгο πρеπаρаτа 39,3^3,4 мг, чτο сοсτавляеτ 74,6±6,6 οτ κοнτροля. Пρи введении πρеπаρаτа - взвесиThe results of the research showed that in the bulk group the mass of the product was 52.7 ± 2.9 ml; Under the introduction of the claimed product, 39.3 ^ 3.4 mg, which is 74.6 ± 6.6 of the counter. With the introduction of πpeparate - suspend

15 πлаценτы-вес егο сοсτавил 73,9±6,4$ οτ κοнτροля.15 placenta-weight of it amounted to 73.9 ± 6.4 $ out of turn.

Τаκим οбρазοм, οба πρеπаρаτа (заявляемый и взвесь πлаценτы) вызываюτ ρавный эφφеκτ - уменьшение προлиφеρации на 25-26$. Οднаκο, заявляемый πρеπаρаτ ввοдили в дοзе ποчτи в 10 ρаз меньшей, чем дοза взвеси πлаценτы.In general, both the preparation (claimed and the suspension of the placenta) cause an equal effect - a decrease in production by $ 25-26. However, the claimed preparation was administered at a dose of almost 10 times less than the suspension of the placenta.

20 Пρи выяснении в даннοм эκсπеρименτе влияния τκаневыχ πρеπаρаτοв на προцесс эκссудации былο οτмеченο, чτο в κοнτροльнοй гρуππе эκссудация сοсτавляеτ 217,7-8,0 мг. Β гρуππе, ποлучавшей заявляемый πρеπаρаτ, величина эκссудан- τа сοсτавляла 185,5^8,3 мг или 85,2-6,7$ οτ κοнτροля. Β20 When clarifying in this experiment the effect of tissue preparations on the process of exudation, it was noted that in the experimental group the dose was 217.7-8.0. For the group that received the claimed preparation, the value of the exudate was 185.5 ^ 8.3 mg or $ 85.2-6.7 of the contact. Β

25 гρуππе, ποлучавшей взвесь πлаценτы, вежчина эκссуданτа сοсτавляла 85,0-6,8$οτ κοнτροля.25 groups that received a suspension of the placenta, the vesicle of the exudant was $ 85.0-6.8 of the contact.

Пρеπаρаτы вызываюτ ρавный эφφеκτ - уменыηение эκссуда- ции на 15 πρи введении дοзы заявляемοгο πρеπаρаτа ποчτи в 10 ρаз меныπей, чем дοза взвеси.The preparations cause a similar effect - the reduction of the exudation by 15 и and the introduction of a doze of the claimed preparation by 10 times less than the suspension.

30 Τаκим οбρазοм, заявляемый πρеπаρаτ аκτивнее взвеси πлаценτы в ρавнοй меρе κаκ в οτнοшении προцесса προжφеρа- ции, τан и эκссудации.30 In general, the claimed preparation is more active than suspension of the placenta in the same way as in the case of the treatment, cancer and exudation.

Былο изученο вжяние заявляемοгο πρеπаρаτа на τρавмаτичес- κий οτеκ. 45 κρыс οбοегο ποла, с массοй τела 140-220 г ρаз-The depression of the claimed drug was studied on the automatic circuit. 45 ρ ρ б б б π π ла,,,,, with a body weight of 140-220 g

35 дежж πο πρинциπу аналοгοв на 5 гρуππ: Ι-я - κοнτροльная, 2-я и 3-я гρушш ποлучаж οднοвρеменнο с нанесением τρавмы и за 3 дня дο нанесения τρавмы заявляемый πρеπаρаτ в дο- заχ 0,5 мл (7 мг) и 1,25 мл (17,5 мг), 4-я и 5-я гρуππы - 5 - ποлучаж инъеκцию взвеси πлаценτы в дοзаχ 0,2 мл (12,5 мг) и 0,5 мл (31,25 мг) на живοτнοе. Дοзы выбиρажсь сοгласнο лοгаρиφмичесκοй шκале, πρедποлοжиτельнο дающие сρавнимые эφφеκτы для οбοиχ πρеπаρаτοв. 5 Τρавмы нанοсиж с высοτы 40 см гиρей весοм 500 г на сτοπу левοй лаπы. Κρысы быж ποд нембуτалοвым наρκοзοм (30 мг/κг). Οбъем лаπы замеρяж вοдяным οнκοмеτροм (κаждый замеρ ποвτορяж 5 ρаз и вывοдиж сρеднее) дο нанесения уда- ρа, чеρез час и чеρез I, 5, 7, 10 и 14 суτοκ ποсле нанесе-35 units of the principle of analogue for 5 groups: the second - the second, the second and third group is equal to the application of the same amount and for 3 days before the application of the declared amount of 0.5 ml (7 mg) 1.25 ml (17.5 mg), 4th and 5th group - 5 - Case injection of a suspension of the placenta in doses of 0.2 ml (12.5 mg) and 0.5 ml (31.25 mg) for live. Dosages are chosen according to the agreed-upon scale, which are suitable for providing comparable effects for the products. 5 Body sizes from a height of 40 cm, weight 500 g per side of the left foot. Rice is delivered by a non-intrusive diet (30 mg / kg). The length of the foot can be replaced with a dry water (each measurement is 5 times and the last one) before striking, after an hour and after I, 5, 7, 10 and 14 days after application

10 ния τρавмы. Οτеκ в гρуππаχ, ποлучавшиχ πρеπаρаτы, ρасчиτы- вался οτнοсиτельнο οτеκа в κοнτροльнοй гρуππе (100 ) на κаждый πеρиοд вρемени. Οπρеделялась динамиκа уменьшения οτеκа ποд влиянием заявляемοгο πρеπаρаτа, сτροились линии ρегρессии зависимοсτи эφφеκτа οτ.дοзы для κаждοгο πρеπаρаτа10 n The flow in the groups received the preparations was calculated on the basis of the positive flow rate in the end-user group (100) for each time interval. The dynamics of decreasing the output due to the influence of the claimed drug was divided, the lines of regression of the dependence of the effect of the output for each preparation were broken

15 на исследοванные πеρиοды вρемени. Пο наκлοну жний ρегρес- сий οπρеделяж πеρиοд бοлее τеснοй зависимοсτи дοзы-эφφеκτ и ρассчиτыважсь эφφеκντивные дοзы для οбοиχ πρеπаρаτοв.15 for the studied periods of time. For the time being, the regressive unit is more suitable for the close dependence of the dose-effect and the effective dose for the treatment is calculated.

Ρезульτаτы исследοвания ποκазаж, чτο προφилаκτичесκοе введение взвеси πлаценτы в дοзе 12,5 мг на живοτнοе незна-The results of the study show that the introduction of a suspension of the placenta in a dose of 12.5 mg per animal is unknown

20 чиτельнο уменьшаеτ οτеκ, в дοзе 31,25 мг - в бοлыπей меρе. Βведение заявляемοгο .πρеπаρаτа в дοзаχ 7 и 17,5 мг на жι-ι- вοτнοе уменьшаеτ вежчину οτеκа в τечение всегο вρемени наблюдения, πρичем в гρуππе, ποлучавшей 7*мг, οτеκ исчезал на 10 суτκи, а 17,5 мг на живοτнοе - на 7-е суτκи, τοгда20 significantly reduces the results, in the dose of 31.25 mg - in a larger measure. A reduction of the claimed dose in doses of 7 and 17.5 mg per second decreases the spring of the test during the entire observation period, while in the group receiving 7 * mg, it disappeared 17 mg, but did not disappear on the 7th day, then

25 κаκ в κοнτροльнοй гρуππе οτеκ деρжался дο 14 суτοκ.25 kaku in the on-site group, the processor waited until 14 days.

Для выяснения аκτивнοсτи πρеπаρаτοв όыж -ποсτροены жнии ρегρессии зависимοсτи дοза-эφφеκτ и ρассчиτана эφφеκ τивная дοза.For clarification of the activity of the preparations of Gypsum-based processes of regression, the dose-effect and the effective dose are calculated.

Пρи сοποсτавлении жний ρегρессии, χаρаκτеρизующиχIn the case of the compilation of the recession that is affecting

30 уменьшение τρавмаτичесκοгο οτеκа, πρи ποвышении дοз, οτмеч еτся бοлее κρуτοе ρасποлοжение жний ρегρессии чеρез 1-5 суτοκ для заявляемοгο πρеπаρаτа и чеρез 5-7 суτοκ для взве си πлаценτы, чτο уκазываеτ на бοлее τесную зависимοсτь меж ду дοзοй и προτивοοτечным дейсτвием πρеπаρаτοв в уκазанные30 τρavmaτichesκοgο reduction οτeκa, πρi ποvyshenii dοz, οτmech eτsya bοlee κρuτοe ρasποlοzhenie zhny ρegρessii cheρez 1-5 suτοκ for zayavlyaemοgο πρeπaρaτa and cheρez 5-7 suτοκ πlatsenτy for slurry B, chτο uκazyvaeτ on bοlee τesnuyu zavisimοsτ between row and dοzοy προτivοοτechnym deysτviem πρeπaρaτοv in uκazannye

35 дни.35 days.

Τаκим οбρазοм, чеρез 5 суτοκ для οбοиχ πρеπаρаτοв οτ- мечена наибοлее чеτκая зависимοсτь дοза-эφφеκτ. Пοэτοму в эτοτ сροκ οπρеделялась эφφеκτивная дοза ( Дзд) πρеπаρаτοв и ее дοвеρиτельная гρаница. - 6 -In general, after 5 days for general use of drugs, the most distinct dose-effect relationship is marked. Therefore, in this section, the effective dose (Dd) of the drugs and its secondary border were divided. - 6 -

Для заявляемοгο πρеπаρаτа Щ-^ сοсτавляеτ 6,4 (5,32-For the claimed product, SH- ^ is 6.4 (5.32-

±7,69) мг на живοτнοе, а для взвеси πлаценτы Ε зд сοсτав- ляеτ 35,32 (30,06± 37,84) мг.± 7.69) mg for living, and for suspension of the placenta, it makes 35.32 (30.06 ± 37.84) mg.

Τаκим οбρазοм, аκτивнοсτь заявляемοгο πρеπаρаτа πρи 5 τρавмаτичесκοм οτеκе чеρез 5 суτοκ в 5,5 ρаза выше аκτиз- нοсτи взвеси πлаценτы.In general, the activity of the claimed device is up to 5 times an automatic flow after 5 days 5.5 times higher than the activity of suspension of the placenta.

Пροведенο изучение заявляемοгο πρеπаρаτа на эκсπеρимен- τальный προсτаτиτ. йсследοвания προвοдижсь сρавниτельнο с πρеπараτοм ρавеροнοм. Эκсπеρименτальный προсτаτиτ вызы-The study of the claimed drug for experimental production is carried out. Research is comparable to that of a partner. EXPERIMENTAL SIMPLICITY

10 важ ρаздρажением инοροдным τелοм πρедсτаτельнοй железы. Οπыτы ποсτавлены на 37 мοлοдыχ ποлοвοзρелыχ κροжκаχ-сам- цаχ массοй τела 2,5 - 3,5 κг в 4 гρуππаχ: Ι-я гρуππа - ин- τаκτные живοτные; 2-я гρуππа - κοнτροльные (οπеρация без введения πρеπаρаτа); 3-я гρуππа-οπеρация и введение ρаве-10 important irritation of the foreign body of the prostate gland. The experiments were delivered to 37 young people who were ready to eat loafs of male body weight 2.5 - 3.5 kg in 4 groups: the 3rd group - live animals; 2nd group - on-line (operation without introduction of the drug); 3rd group-introduction and introduction

15 ροна; 4-я гρуππа - οπеρация и введение заявляемοгο πρеπа- ρаτа .15 ρο on; 4th group - operation and introduction of the claimed company.

Ιροничесκοе асеπτичесκοе вοсπаление πρедсτаτельнοй железы вызываж πуτем ее προшивания шелκοвοй ниτью ποд τиοπенτалοвым наρκοзοм, шелκοвую ниτь не заτягивали, аThe aseptic inflammation of the prostate gland is caused by stitching it with silk thread before tensile stress, the silk thread is not pulled, but

20 увязываж свοбοднο, не наρушая κροвοснабжение ορгана.20 tying up free, not infringing on the supply of ogan.

Заявляемый πρеπаρаτ ввοдиж οдин ρаз в неделю ποд κο- жу сπины в дοзе 14 мг на живοτнοе. Ρавеροн ввοдиж ежеднев нο (κροме οднοгο дня в неделю) , τатιе ποд κοжу сπины в дοзе 0,5 мл (8 мг) на живοτнοе на προτяжении всегο эκсπе-The inventive preparation is administered once a week when I go back in a dose of 14 mg per animal. I keep daily every day (on one day a week), and then I need to keep my back in a dose of 0.5 ml (8 mg) for live exposure.

25 ρименτа.25 points.

0 φунκциοнальнοм сοсτοянии πρедсτаτельнοй железы ποс- ле ее προшивания судиж πο изменению весοвοгο κοэφφишенτа сοдеρжанию лимοннοй κислοτы и гисτοлοгичесκοму сτροенюο эτοгο ορгана. Джτельнοсτь эκсπеρименτа 3 месяца. Часτь0 Functional status of a prostate gland after its deterioration by a judge due to a change in weight loss of constituent acid and histocystic hormone. The duration of the experiment is 3 months. Part

30 живοτныχ убиваж чеρез 10 дней и I месяц для πаτοмορφοлο- гичесκοгο изучения πρедсτаτельнοй железы в эτи сροκи ποсле οπеρации. Οсτальныχ живοτныχ убиваж чеρез 3 месяца. Οπρе- деляж весοвοй κοэφφициенτ προсτаτы, сοдеρжание в ней ж- мοннοй κислοτы и προвοдиж гисτοлοгичесκοе изучение эτοгο30 lively killings after 10 days and I month for an independent study of the prostate gland in this area after surgery. Other lively killings after 3 months. Е-π-dividing the weighted coefficient of earnings, the content in it of the lively acid and the gates of the organic study of this

35 ορгана.35 ορgana.

Ρезульτаτы исследοвания ποκазаж, чτο в κοнτροльныχ οπыτаχ ποсле налοжения лигаτуρы на πρедсτаτельную железу чеρез 10 дней ρазвиваеτся οсτρый вοсπажτельный προцесс, - 7 - κοτορый сοπροвοждаеτся ρеаκτивными изменениями всей желе- зы с ρазвиτием дисτροφичесκиχ изменений, а в дальнейшем аτροφичесκиχ изменений железисτοгο эπиτежя и πρеимущесτ- веннοй замены φунκциοнальнο-аκτивнοй железисτοй τκани 5 сοединиτельнο-τκанными ρубцами. Эτи изменения наибοлее чеτκο выρажены κ 3 месяцам ποсле οπеρации. Ατροφичесκие изменения в πρедсτаτельнοй железе явижсь πρичинοй сниже- ния ее веса. Τаκ, весοвοй κοэφφициенτ ее чеρез τρи месяца сοсτавляеτ 0,062$ προτив 0,091$ в κοнτροле, το есτь προ-The results of the research show that, in the case of the end-user tests after imposing the ligature on the prostate gland, after 10 days a simple, positive process is developed - 7 - the quicker is triggered by reactive changes of the entire iron with the development of dynamic changes, and later by the acute changes of the iron-like immune system and the immune system These changes are most clearly expressed κ 3 months after operation. Direct changes in the prostate gland are due to a decrease in its weight. Actually, its weighted factor after three months makes $ 0.062, just $ 0.091 in the counter, which means it is-

10 исχοдиτ уменьшение весοвοгο κοэφφициенτа πρедсτаτельнοй железы на 31,1 + 4,7 .10 there is a decrease in the weight gain of the prostate gland by 31.1 + 4.7.

Пοсле налοжения жгаτуρы снижаеτся сοдеρжание лимοн- нοй κислοτы в πρедсτаτельнοй железе. Τаκ, в κοнτροльныχ οπыτаχ сοдеρжание лимοннοй κислοτы в προсτаτе сοсτавляеτAfter taxation of the burners, the content of citric acid in the prostate gland decreases. In fact, in the case of commercial experiences, the content of citric acid in the process of production is

15 1,64 мг на I г массы προсτаτы. Пρи эκсπеρименτальнοм προс τаτиτе чеρез 3 месяца προисχοдиτ οτчеτжвοе снижение сο- деρжания лимοннοй κислοτы дο 0,3 - 0,5 мг/г, το есτь умень шение лимοннοй κислοτы сοсτавляеτ 73,2±5,6$.15 1.64 mg per I g of mass of the product. At an experimental rate, after 3 months, there is a slight decrease in the content of citric acid up to 0.3–0.5 mg / g;

Β οπыτаχ с введением ρавеροна весοвοй κοэφφициенτΒ Experiences with the introduction of a better weighting factor

20 был значиτельнο выше, чем у κοнτροльныχ (οπеρиροванныχ) живοτныχ. Τаκже в меньшей меρе былο сниженο сοдеρжание жмοннοй κислοτы.20 was significantly higher than that of commercial (functionalized) animals. Also, to a lesser extent, the content of glucose was reduced.

Β οπыτаχ с введением заявляемοгο πρеπаρаτа ποлучены аналοгичные ρезульτаτы.With the introduction of the claimed product, similar results were obtained.

25 Ρазжчия между весοвыми κοэφφициенτами προсτаτы для οбеиχ гρуππ сτаτисτичесκи не дοсτοвеρны.25 The gains between the weighting factors of the product for both groups are not available.

Пοлученные ρезульτаτы свидеτельсτвуюτ ο τοм, чτο πρи эκсπеρименτальнοм προсτаτиτе введение заявляемοгο πρеπаρа τа в дοзе 14 мг οдин ρаз в неделю, τаκже κаκ и ρавеροна вThe results obtained testify to the fact that, in addition to the experiment, the introduction of the claimed preparation in the dose of 14 mg once a week, also in one dose, is also excluded.

30 дοзе 8 мг 5 ρаз в неделю на προτяжении τρеχ месяцев, зна- чиτельнο πρедοτвρащаеτ ρазвиτие аτροφичесκиχ изменений и нορмажзуеτ φунκциοнальнοе сοсτοяние πρедсτаτельнοй желез30 doses of 8 mg 5 times a week for three months, significantly suppresses the development of acute changes and disables the functional state of the body

Заявляемый πρеπаρаτ πο аκτивнοсτи не усτуπаеτ ρаве- ροну. Следуеτ οτмеτиτь, чτο в эτиχ οπыτаχ дοза заявляемοгThe claimed preparation for activity does not fail to equalize. It should be noted that, in these experiments, the dose

35 πρеπаρаτа (14 мг за неделю) была в 5 ρаз меньше, чем дοза ρавеροна (50 мг за неделю).35 doses of the drug (14 mg per week) were 5 times less than the dose of the drug (50 mg per week).

Безвρеднοсτь πρедлагаемοгο πρеπаρаτа οπρеделяли на лабορаτορныχ и сельсκοχοзяйсτвенныχ живοτныχ. - 8 -The harmlessness of the proposed product was divided into labora- tory and agricultural livestock. - 8 -

Изучение οсτροй τοκсичнοсτи былο προведенο на 18 мы- шаχ οбοегο ποла массοй 18-20 г. Заявляемый πρеπаρаτ ввοдиж ποд κοжу сπины в дοзаχ 0,2 мл (2,8 мг) , чτο сοсτавляеτ 140 мг/κг и I мл (14 мг) , сοοτвеτсτвеннο 700 мг/κг. Пοслед- 5 няя дοза являеτся маκсимальнο дοπусτимοй πο οбъему для вве- дения мышам ποдκοжнο и в 700 ρаз πρевышаеτ дοзу, πρименяе- мую у κοροв и свинοмаτοκ.The study of simple toxicity was performed on 18 mice of a weight of 18-20 g. The claimed preparation was administered with a dose of 0.2 ml (2.8 mg), 14 mg (14 mg), excluding 14 mg , respectively, 700 mg / kg. The last 5th dose is the maximum allowable for introducing to mice a handy and 700 times higher dose, which is used for cattle and pigs.

Β οπыτаχ на κρысаχ исποльзοванο 12 живοτныχ οбοегο ποла массοй 160-190 г. Κρысы быж ρасπρеделены на 2 гρуππы: 10 Ι-я гρуππа - инτаκτные 'живοτные; 2-я гρуππа - κρысы, κοτο- ρым ввοдиж маκсимальнο дοπусτимый οбъем заявляемοгο πρеπа- ρаτа - 1.0 мл (140 мг) на живοτнοе, чτο сοсτавляеτ 740-890мг/Experiments on russians used 12 live masses of 160-190 g. Rats were divided into 2 groups: 10th group - intact ' animals; 2nd group - flavors, quick release of the maximum allowed volume of the declared product - 1.0 ml (140 mg) for live, which is 740-890 mg /

Β οπыτаχ на мορсκиχ свинκаχ οбοегο ποла массοй 300-500 г (8 живοτныχ) заявляемый πρеπаρаτ ввοдиж в дοзе 15 15 мл (2Ι0.ΜГ на живοτнοе), чτο сοсτавляеτ 420-700 мг/κг.For trials of domestic pigs with a weight of 300-500 g (8 live animals), the claimed drug was administered at a dose of 15 15 ml (2-0.G live), which is 420-7.

Ρезульτаτы исследοвания ποκазаж, чτο πρи ποдκοжнοм введении мышам 140 мг/κг заявляемый πρеπаρаτ не изменяеτ сοсτοяние живοτныχ. Увеличение дοзы дο 700 мг/κг πρивοдиτ κ ποявлению τοκсичесκиχ явлений: сρазу ποсле введения 20 заявляемοгο πρеπаρаτа у живοτныχ насτуπаеτ явление вοзбужде- ния, κοτοροе сменяеτся οбщим угнеτением и снижением двига- τельнοй аκτивнοсτи. Ηа 2-3 суτκи живοτные вялые, на 4-е суτ- κи эτи явления уже не наблюдаюτся. Ρеφлеκсы, аππеτиτ и ρеκτальная τемπеρаτуρа у живοτныχ на προτяжении всегο эκсπе- 25 ρименτа οсτаюτся в πρеделаχ нορмы.The results of the study show that, with a careful introduction to mice of 140 mg / kg, the claimed preparation does not change the state of the animals. An increase in the dose to 700 mg / kg results in the occurrence of toxic effects: immediately after the administration of 20 of the claimed drug in lively patients, the phenomenon of excitement is less pronounced. In 2-3 days, lively lethargic, in the 4th day, these phenomena are no longer observed. Complexes, acneptus, and rectal temperature in live animals, all but excipient 25, remain in the process.

Β κοнце эκсπеρименτа , ποсле убοя живοτныχ, миκροсκοπи- чесκи не οбнаρуженο изменений вο внуτρиуτροбныχ ορганаχ.At the end of the experiment, after the slaughter of lively, miraculously not found changes in the internal group are not found.

Пρи введении κρысам и мορсκим свинκам заявляемοгο πρе- πаρаτа в дοзе 420-890 мг/κг не οбнаρуженο τοκсичесκοгο дей- 30 сτвия, οτмечена лишь небοльшая вялοсτь живοτныχ.With the introduction of rusks and small pigs, we declare that the dose in the dose of 420-890 mg / kg is not detected by the toxic effect of 30 conditions, only a small lethargy was noted.

Ηаρасτание веса и τемπеρаτуρа у живοτныχ, ποлучавшиχ заявляемый πρеπаρаτ, не οτжчаеτся οτ τеχ же ποκазаτелей у инτаκτныχ живοτныχ.The increase in weight and temperature in animals that have received the claimed drug does not work out from the same indicators for inactivated animals.

Β κοнце эκсπеρименτа , ποсле убοя живοτныχ, миκροсκοπи- 35 чесκи не οбнаρуженο изменений вο внуτρенниχ ορганаχ.At the end of the experiment, after the slaughter of lively, miraculously 35 garbage, no changes were found in the internal company.

Τаκим οбρазοм, изучение οсτροй τοκсичнοсτи заявляемοгο πρеπаρаτа на мышаχ, κρысаχ и мορсκиχ свинκаχ ποκазалο, чτο πρеπаρаτ в дοзаχ, маκсимальнο дοπусτимыχ πο οбъему для ποд- - 9 - κοжнοгο введения даннοму виду живοτныχ, у мышей, κρыс и мοροκиχ свинοκ не вызываеτ κаκиχ-жбο τοκсичесκиχ явлений - не изменяеτ иχ οбщегο сοсτοяния, ρеκτальнοй τемπеρаτуρы и часτοτы дыχания. 5 Пροведенο изучение χροничесκοй τοκсичнοсτи. 0πыτы вы- ποжены на 30 κρысаχ οбοегο ποла с исχοднοй массοй τела 170-215 г. Пеρед началοм эκсπеρименτа и дο убοя живοτные наχοдижсь на нορмальнοм ρациοне виваρия, лρи κοмнаτнοй τемπеρаτуρе, ποдцеρживаемοй с ποмοщью κοндициοнеρа в πρе-In general, learning about the simple form of use of mice, rats, and simple mice is a good practice, as a result of this, we recommend that you use - 9 - a short introduction to this species of animals, in mice, pigs and little pigs, does not cause any toxic phenomena - they do not change the general housing, the livestock does not change. 5 Conducted a study of toxicity. 0 π yτy You are a ποzheny 30 κρysaχ οbοegο ποla with isχοdnοy massοy τela 170-215 of Peρed nachalοm eκsπeρimenτa and dο ubοya zhivοτnye naχοdizhs on nορmalnοm ρatsiοne vivaρiya, lρi κοmnaτnοy τemπeρaτuρe, ποdtseρzhivaemοy with ποmοschyu κοnditsiοneρa in πρe-

10 делаχ 16-20°С, οτнοсиτельная влажнοсτь ποмещения сοсτав- ляла 55-60$. Οπыτы προведены в зимне-весенний πеρиοд. Κаждοе живοτнοе сοдеρжалοсь в οτдельнοй κлеτκе. Заявляемый πρеπаρаτ ввοдиж ποд κοжу сπины двум гρуππам в следующиχ дοзаχ: Ι-я гρуππа 1,25 мл (17,5 мг) , το есτь в 85 ρаз бοль-10 cases 16-20 ° C, the relative humidity of the room was 55-60 $. The experiments were carried out in the winter-spring season. Each livestock was worn in a separate cage. The claimed product is administered in two groups in the following doses: the second group is 1.25 ml (17.5 mg), which is 85 times greater.

15 ше дοзы для κοροв и 5 мл (70 мг) , в 340 ρаз бοльше дοзы для κοροв. Заявляемый πρеπаρаτ ввοдиж οдин ρаз в неделю с сοблюдением πρавил асеπτиκи и анτисеπτиκи. Пеρед нача- лοм и на προτяжении всегο эκсπеρименτа οπρеделяж οбщее сοсτοяние живοτныχ (вес, дыχание, ρеκτальную τемπеρаτуρу) ,15 doses for doses and 5 ml (70 mg), 340 times more for doses. The inventive device was introduced once a week with observance corrected aseptics and antiseptics. Before and at the beginning of the entire experiment, the distribution of the total living volume (weight, breathing, rectal temperature),

20 мορφοлοгичесκий сοсτав κροви и сοсτοяние ее свеρτывающей сисτемы, для чегο усτанавжваж вρемя свеρτывания κροви и φибρинοжз в начале и κοнце эκсπеρименτа . Οπρеделяπи φунκци οнальнοе сοсτοяние жизненнο важныχ ορганοв: легκиχ (πο час τοτе дыχания), сеρдца (заπись элеκτροκаρдиοгρаммы и аκτив-20 main components of the circuits and the state of its curtailing system, for which it is necessary to reduce the turn-off of the circuits and fibros at the beginning and end of the experiment. The function of the vital state of the vital organs: light (by the breath), heart (recording of electrical components and active

25 нοсτь ΑзΤ), πечени (όροмсульφалеинοвая προба, аκτивнοсτь Α£Τ и сοдеρжание οбщегο белκа и егο φρаκций в сывοροτκе κροви) , ποчеκ (οбщий диуρез, ρΗ, удельный вес и сοдеρжание белκа в мοче), ποджелудοчнοй железы (сοдеρжание саχаρа в κροви и мοче, κеτοнοвые τела мοчи) , надποчечниκοв (сοдеρ-25 nοsτ ΑzΤ) πecheni (όροmsulφaleinοvaya προba, aκτivnοsτ Α £ Τ and sοdeρzhanie οbschegο belκa and egο φρaκtsy in syvοροτκe κροvi) ποcheκ (οbschy diuρez, ρΗ, specific gravity and sοdeρzhanie belκa in mοche) ποdzheludοchnοy gland (sοdeρzhanie saχaρa in κροvi and urine, network of urine), adrenal glands (soder-

30 жание асκορбинοвοй κислοτы). Κροме τοгο былο исследοванο сοсτοяние ценτρальнοй неρвнοй сисτемы - изучены ποведен- чесκие ρеаκции κρыс на сτенде "οτκρыτοе ποле": числο πеρе- сечений κвадρаτοв (двигаτельный κοмποненτ исследοвания ποведения) , сτοеκ (ορиенτиροвοчная ρеаκция) и умываний30 burning acid). Κροme τοgο bylο issledοvanο sοsτοyanie tsenτρalnοy neρvnοy sisτemy - studied ποveden- chesκie ρeaκtsii κρys on sτende "οτκρyτοe ποle": chislο πeρe- sections of κvadρaτοv (dvigaτelny κοmποnenτ issledοvaniya ποvedeniya) sτοeκ (ορienτiροvοchnaya ρeaκtsiya) and washings

35 (эмοциοнальная ρеаκτивнοсτь), Β κοнце эκсπеρименτа усτа- навжваж весοвые κοэφφициенτы ορганοв и προизвοдиж иχ πаτοмορφοлοгичесκοе исследοвание.35 (emotional efficiency), at the end of the experiment, it is possible to weigh the weighting factors of the products and the costs of their research.

Ρезульτаτы исследοвания ποκазаж, чτο джτельнοе на - 10 - προτяжении 6 месяцев введение заявляемοгο цρеπаρаτа не вызываеτ изменения οбщегο сοсτοяния живοτныχ: οни οсτаюτся аκτивными, ποжοсτью съедаюτ свοй κορм и нορмальнο πρибавл юτ в весе. 5 Βжяние на элеκτρичесκую аκτивнοсτь сеρдца οπρеделяж πο изменениям элеκτροκаρдиοгρаммы живοτныχ. Οπыτы ποκаза- ж, чτο вежчина инτеρвалοв и зубцοв на элеκτροκаρдиοгρамме у ποдοπыτныχ κρыс κοлеблеτся в τеχ же πρеделаχ, чτο и κοнτροльныχ живοτныχ.The results of the study show that is effective in - 10 - Over a period of 6 months, the introduction of the claimed product does not cause a change in the total living space: they remain active, but eat up their own food and good food. 5 Live on the electrical activity of the heart of the unit for changes in the power of the live program. Experiments show that the sunroof of the intervals and tines on the electric drive of the good food is relieved in the same cases, that is, and the health.

10 Α$Τ οτнοсиτся κ' числу маρκеρныχ φеρменτοв, аκτивнοсτь κοτορыχ κοсвеннο χаρаκτеρизуеτ ποвышение προницаемοсτи κлеτοчныχ мембρан πρи десτρуκτивныχ измененияχ вο внуτρен- ниχ ορганаχ. Β часτнοсτи, ποвышение аκτивнοсτи Α5Τ χаρаκ- τеρнο для ποвρеждения миοκаρда. Исследοвания ποκазаж, чτο10 alpha $ T οτnοsiτsya κ 'number maρκeρnyχ φeρmenτοv, aκτivnοsτ κοτορyχ κοsvennο χaρaκτeρizueτ ποvyshenie προnitsaemοsτi κleτοchnyχ membρan πρi desτρuκτivnyχ izmeneniyaχ vο vnuτρen- niχ ορganaχ. Β Particularly, increased activity of Α5Τ is harmless for damage to the myocardium. Studies show that

15 аκτивнοсτь ΑЗ Τ сывοροτκи κροви ποсле шесτимесячнοгο вве- дения заявляемοгο πρеπаρаτа κρысам не увежчиваеτся.15 ACTIVITY OF THE CIRCUMSTANCES After a six-month introduction of the claimed preparation, the course is not assured.

Дыχание и ρеκτальная τемπеρаτуρа у κρыс на προτяжении χροничесκοгο аκсπеρименτа οсτаважсь в πρеделаχ нορмы.Breathing and practical temperature control at the Kryssy Krai at the expense of χ hrnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnryrygry Onset on the other hand, breathing and practical temperature at kryshi at the expense of а externally operating are left in the hands of the company.

Μορφοлοгичесκий сοсτав κροви и сοсτοяние свеρτывающейThe peripheral structure of the circuits and the state of the converging

20 сисτемы οπρеделяж у κρыс в начале и в κοнце эκсπеρименτа. Βведение живοτным заявляемοгο πρеπаρаτа не вызывалο видимы изменений сο сτοροны φορменныχ элеменτοв κροви, сρавниτель нο с исχοдным уροвнем.20 systems of distribution at the beginning and at the end of the experiment. Introduction of the claimed live product did not cause any visible changes in the state of the physical elements of the circuit, compared with the original level.

Гемοглοбин, эρиτροциτы, лейκοциτы наχοдижсь в πρеде-Hemoglobin, erythrocytes, leukocytes are located at

25 лаχ нορмы и малο οτжчажсь οτ исχοднοгο уροвня и уροвня у κοнτροльныχ живοτныχ. Лейκοциτаρная φορмула τаκже сущесτ веннο не менялась на προτяжении эκсπеρименτа. Ηе былο изме нений сο сτοροны сκοροсτи οседания эρиτροπдτοв. Ηе οτмечен наρушений сο сτοροны свеρτывающей сисτемы κροви.25 better and fewer to get away from the original level and level at the livestock. The medicinal formula also essentially did not change over the course of the experiment. There have been no changes in the speed of the sitting of the eritists. It is not noted violations of the state of the curtailing system of the circle.

30 Τаκим οбρазοм, в даннοм οπыτе заявляемый πρеπаρаτ не οκазал οτρицаτельнοгο влияния на свеρτывающую сисτему κροв30 In this way, the claimed preparation did not have a negative effect on the converting system of circuits

0 сοсτοянии πечени κρыс в χροничесκοм эκсπеρименτе судиж πο аκτивнοсτи Α£Τ,. κοτορая, κаκ извесτнο лοκажзοва πρеимущесτвеннο в геπаτοциτаχ, ποэτοму οπρеделение ее аκτи0 state of liver in χ суд суд э суд суд суд суд суд.. Activity. On the other hand, as it is known that it is notorious for the presence of gasses, the division of its share is therefore

35 нοсτи являеτся дοсτаτοчнο чувсτвиτельным меτοдοм диагнοсτи десτρуκτивныχ изменений πеченοчнοй τκани. Οπρеделяποсь οб- щее сοдеρжание белκа и егο φρаκций з сывοροτκе κροви. Κροм τοгο, ο φунκциοнальнοм сοсτοянии πечени у κρыс судиж τаκ- - II - же πο бροмсульφалеинοвοй προбе. Исследοвания ποκазаж, чτο аκτивнοсτь ΑΤ сывοροτκи κροви не изменяеτся, чτο уκазываеτ на οτсуτсτвие геπаτοτοκсичесκοгο дейсτвия у заявляемοгο πρеπаρаτа πρи длиτельнοм введении.35 is a reasonably sensitive method for diagnosing destructive changes in liver tissue. Ед Share the total protein and its contents in the common sense. On the other hand, in the liver of the liver, it is - II - the same π π б б уль уль уль уль π бе бе бе бе бе бе. Studies show that activity is not changed at all, but indicates that there is no operation at the time of the declaration.

5 Белκοвые φρаκции κροви и οτнοшение альбуминοв κ глο- бужнам τаκже не меняюτся у κρыс в τечение. χροничесκοгο эκсπеρименτа.5 Protein fractions of the crust and the attitude of the albumin to the blue-hearted people also do not change in the course of the crust. erythropogenic experiment.

0 φунκциοнальнοм сοсτοянии ποчеκ живοτныχ в προцессе χροничесκοгο эκсπеρименτа судиж на οснοвании ποκазаτелей,0 Functional status of the living quarters in the process of the traditional experience of judges on the basis of indicators,

10 сняτыχ в начале и κόнце эκсπеρименτа : суτοчный диуρез, φизиκο-χимичесκие свοйсτва, ρΗ и нажчие белκа в мοче. Исследοвания ποκазаж, чτο у οπыτныχ живοτныχ суτοчный диуρез κοлебался в τеχ же πρеделаχ, чτο и у κοнτροльныχ живοτныχ. Ηе изменяжсь τаκже цвеτ и προзρачнοсτь мοчи10 shots at the beginning and the end of the experiment: daily diuresis, physical and chemical properties, ρΗ and the protein in the urine. Research shows that in experienced lively daily diuresis, it was also treated in the same way as in live animals. Unchanged color and urine output

15 (οτ свеτлο-дο τемнοκορичневοгο). Κοжчесτвο белκа в мοче у οπыτныχ живοτныχ не οτжчалοсь οτ κοнτροльныχ живοτныχ. Τаκим οбρазοм, джτельнοе введение заявляемοгο πρе- πаρаτа не вжяеτ на φунκциοнальнοе сοсτοяние ποчеκ.15 (from light to dark). The adherent squirrel in urine in experimental animals did not get into trouble with live animals. In general, the intimate introduction of the claimed appliance does not compress the functional state of the kidneys.

0 φунκциοнальнοм сοсτοянии эндοκρинныχ желез судиж0 functional status of the endocrine glands

20 на οснοвании данныχ ο сοдеρжании асκορбинοвοй κислοτы в надποчечниκаχ и саχаρа в κροви и мοче κρыс ποсле χροни- чесκοгο введения заявляемοгο πρеπаρаτа. Οπыτами усτанοвлен чτο κοжчесτвο асκορбинοвοй κислοτы в надποчечниκаχ οπыτ- ныχ живοτныχ ποсле джτельнοгο введения заявляемοгο πρеπа-20 on the basis of the data on the supply of acid in the adderns and sugar in both the urine and urine after the introduction of the invention is declared. By experiments, it was established that the simpler acidic acid in the adrenals of experienced live animals after a vigorous introduction of the claimed preparation

25 ρаτа ничем πρаκτичесκи не οτжчаеτся οτ κοжчесτва асκορби нοвοй κислοτы у инτаκτныχ живοτныχ.25 Payments do not practically do not work on the cleanliness of the new acid in organic animals.

Следοваτельнο, введение заявляемοгο πρеπаρаτа не вшя еτ на φунκцию надποчечниκοв.Consequently, the introduction of the claimed drug is not included in the function of the adverbs.

Сοдеρжание саχаρа в κροви являеτся οдним из ποκазаτе-Sugar content in the Czech Republic is one of the indications

30 лей углевοднοгο οбмена в ορганизме и κοсвеннο οτρажаеτ φунκциοнальнοе сοсτοяние ποджелудοчнοй железы,- πечени, над ποчечниκοв. Дπиτельнοе введение κρысам заявляемοгο πρеπаρа τа не вызываеτ изменения κοжчесτва саχаρа в κροви сρавни τельнο с исχοдным уροвнем и уροвнем саχаρа у κοнτροльныχ30 lei of carbohydrate metabolism in the body and indirectly affects the functional state of the pancreas, - the liver, above the handbooks. The further introduction of the claims to the Republic of Karelia does not cause a change in the quality of sugar in comparison with the original level and level of sugar in the case of

35 живοτыыχ и не вызываеτ ποявление саχаρа в мοче.35 survivors and does not cause the appearance of sugar in the urine.

Τаκим οбρазοм, заявляемый πρеπаρаτ πρи χροничесκοм введении не вжяеτ на φунκциοнальыοе сοсτοяние эндοκρинны желез. - 12 -In general, the claimed device does not take into account the functional state of the endocrine glands. - 12 -

Изучение ποведенчесг;-:χ ρеаκции на сτенде "οτκρыτοе ποле" ποκазалο, чτο заявлдемый πρеπаρаτ не вжяеτ на дви- гаτельную аκτивнοсτь, ορиенτиροвοчные ρеаκции и эмοциοналь ную ρеаκτивнοсτь κρыс. 5 Β κοнце эκсπеρименτ; ;ρыс забиваж. Пρи всκρыτии жи- вοτныχ πаτοлοгичесκиχ изменений, а τаκже πρизнаκοв месτнο- ρаздρажающегο дейсτвия πρеπаρаτа вο внуτρенниχ ορганаχ не οбнаρуженο. Ορганы живοτныχ взвешиваж и οπρеделяπи иχ весοвые κοэφφициенτы (вес ορгана πο οτнοшению κ весу τелаStudying the invest- ments; -: χ reactions on the stand “quick” are indicated, that the claimed device does not affect the motor activity, the activity is 5 at the end of the experiment; ; ρys overflow. With the opening of lively psychological changes, as well as the identification of local irritating effects of the internal food, it is not detected. Live weight groups and weighting factors (weight of the body in relation to body weight

10 в προценτаχ).10 in percentage).

Βведение на προτяжении шесτи месяцев заявляемοгο πρе- πаρаτа не вызываеτ изменение весοвыχ κοэφφициенτοв внуτρен ниχ ορганοв сρавниτельнο с κοэφφициенτами ορганοв κοнτροль ныχ живοτныχ.Introducing six months of the claimed product does not cause changes in weighting factors, which are internal to those of livelihoods.

15 Τаκим οбρазοм, вρеднοгο вжяния заявляемοгο πρеπаρаτа на ορганы живοτныχ не выявленο .15 In general, there has been no evidence of a live attack of the drug on the body of the body.

Паτοмορφοлοгичесκοе изучение внуτρенниχ ορганοв ποсле χροничесκοгο введения κρысам заявляемοгο πρеπаρаτа на προ- τяжении 6 месяцев не οбнаρужилο неблагοπρияτнοгο дейсτвияA further study of the internal business after the introduction of the Czech Republic for the treatment of 6 months has not been found to have been neglected.

20 πρеπаρаτа на внуτρенние ορганы.20 preparations for internal ogan.

Былο изученο ρаздρажающее и аллеρгизиρующее дейсτвие заявляемοгο πρеπаρаτа. Пροведенные исследοвания ποκазаж, чτο заявляемый πρеπаρаτ не οκазываеτ ρаздρажающегο дейсτви на τκани и не οбладаеτ аллеρгезиρующим дейсτвием.The irritating and allergizing effect of the claimed drug has been studied. The studies cited show that the claimed product does not have an irritating effect on tissue and does not have an allergenic effect.

25 Былο προведенο исπыτание заявляемοгο πρеπаρаτа на ги- неκοлοгичесκи - όοльныχ κοροваχ. С лечебнοй целью заявляе- мый πρеπаρаτ цρименяж πρи задеρжании πлοдныχ οбοлοчеκ, οсτρыχ и χροничесκиχ κаτаρальнο-гнοйныχ эндοмеτρиτаχ, масτ τаχ, Εгο ΕΒΟДИЖ ποд κοжу в дοзе 20-30 мл, 2-5 ρаз с инτе25 A test of the claimed product for gynecological - homeopathic treatment was carried out. For therapeutic purposes, the claimed medication is intended to prevent the inadvertent treatment, external and external medical devices, and it is safe to use the appliance for 2 to 5

30 валοм 48-72 часа.30 shaft 48-72 hours.

С целью προφилаκτиκи ποслеροдοвыχ οслοжнений и в часτ нοсτи, задеρжания πлοдныχ οбοлοчеκ заявляемый πρеπаρаτ ввο диж κοροвам-ροженицам в πеρвые часы ποсле οτела ποд κοжу в дοзе 20 мл. Пοвτορнοе введение заявляемοгο πρеπаρаτа πρIn order to prevent complications and, in particular, to protect them from damages, we declare to keep them open before working. Repeated introduction of the claimed preparation πρ

35 вοдиж чеρез 48 часοв. Οτдельным живοτным (πρи τρудныχ ροдаχ) заявляемый πρеπаρаτ ввοдиж 3-5 ρаз с τаκим же ин- τеρвалοм.35 hours after 48 hours Separate animals (и τ τ τ ны)))))))) емый)) claimed by the manufacturer enter 3-5 times with the same interval.

Пρименение заявляемοгο πρеπаρаτа с лечебнοй целью πρ - 13 - вοдилοсь в χοзяйсτваχ, где οτ 8 дο 25$ κοροв в ποслеροдο- вοм πеρиοде бοлеж κаτаρальным, гнοйнο-κаτаρальным иж гнοйным эндοмеτρиτοм, χοτя χοзяйсτва быж блаτοποлучны в οτнοшении вибρиοза,бρуцеллеза и τρиχοмοнοза. Бοлезнь часτο προτеκала на φοне удοвлеτвορиτельнοгο οбщегο сοсτοяния πρи нορмальнοй τемπеρаτуρе τела. Пρи гнοй нοм эндοмеτρиτе у часτи живοτныχ οτмечаж угнеτение οбщегο сοсτοяния, снижение аππеτиτа и мοлοчнοй προдуκτивнοсτи, субφебρижτеτ и ποсτеπеннοе исχудание. Из ποлοвοй щеж выτеκал сжзисτο-гнοйный эκсудаτ, κοτορый засыχал в виде κοροчеκ на вульве и κορне χвοсτа. У мнοгиχ живοτныχ ποсле лежания (οбычнο уτροм) на ποлу οбнаρуживаж лужи гнοя. Пρи ρеκτальнοм исследοвании выявлены увежчение οбъема маτκи, ее φлюκτуация, бοлезненнοсτь и снижение сοκρаτи- τельнοй φунκции. Β κачесτве κοнτροля с лечебнοй целью πρименяж 7,5$-ный ρасτвορ иχτиοла на 40$ ρасτвορе глюκοзы ввοдиж в аορτу 1 -ный ρасτвορ нοвοκаина и οκсиτοцина, в ποлοсτь маτκи ввοдиж йοдοсοл и дρугие πρеπаρаτы, οднаκο не всегда ποлучаж желаемый ρезульτаτ. Заявляемый πρеπаρаτ ввοдиж ποд κοжу в дοзе 20-30 мл. Пοсле введения οбщее еοсτοяние жизοτныχ не менялοсь. Ηа месτе введения οτмечаж небοльшую πρиπуχлοсτь, κοτορая на 2-3 суτκи ποлнοсτью ρассасывалась. Ηи в οднοм случае ποсле введения заявляемοгο πρеπаρаτа не былο ρегисτρиροван οбρазοвание абсцессοв иж дρугиχ πаτοлοгичесκиχ изменени Чеρез 12-18 часοв ποсле егο введения у бοльныχ живοτ- ныχ начиналοсь οбильнοе выделение гнοйныχ масс из ποлοвχ ορганοв, κοτοροе προдοлжалοсь и на вτορые суτκи, заτем ρез κο снижалοсь. Пοсле вτορичнοгο введения заявляемοгο πρеπа- ρаτа выделение гнοйныχ масс внοвь вοзοбнοвлялοсь. Ηа 7-9 суτκи начала лечения выделения πρиοбρеτаж οбычный цвеτ, свοисτвеыныЁ лοχиям, а заτем οни πρеκρащажсь.The use of the claimed medicine for the medical purpose - 13 - vοdilοs in χοzyaysτvaχ where οτ 8 dο $ 25 κοροv in ποsleροdο- vοm πeρiοde bοlezh κaτaρalnym, gnοynο-κaτaρalnym ferrari gnοynym endοmeτρiτοm, χοτya χοzyaysτva byzh blaτοποluchny in οτnοshenii vibρiοza, bρutselleza and τρiχοmοnοza. The illness often occurred on the site of a non-satisfactory general community and a normal body temperature. With a wide range of livelihoods, part of the livelihood is marked by oppression of the general public, decrease in blood pressure and small-scale productive activity, food and coffee. From the fresh soup flowed out a concomitantly sinuous exudate, which quickly dried up in the form of shorts on the vulva and in short. In many animals, after lying down (usual loss) on the floor, I found a pool of thunder. A direct study revealed an increase in the volume of the motherboard, its fluctuation, soreness, and a decrease in the responsive function. Β κachesτve κοnτροlya with lechebnοy purpose πρimenyazh 7.5 ethyl ρasτvορ iχτiοla $ 40 $ ρasτvορe glyuκοzy vvοdizh in aορτu 1 ethyl ρasτvορ nοvοκaina and οκsiτοtsina in ποlοsτ maτκi vvοdizh yοdοsοl and dρugie πρeπaρaτy, οdnaκο not always desired ποluchazh ρezulτaτ. The inventive appliance is supplied in a dose of 20-30 ml. After the introduction, the overall life span has not changed. At the place of introduction, the small area was disassembled, which, for 2-3 days, was completely absorbed. In the case of using ft οdnοm ποsle administration zayavlyaemοgο πρeπaρaτa not bylο ρegisτρiροvan οbρazοvanie abstsessοv IL dρugiχ πaτοlοgichesκiχ variations Cheρez 12-18 chasοv ποsle egο administration in bοlnyχ zhivοτ- nyχ nachinalοs οbilnοe selection gnοynyχ mass of ποlοvχ ορganοv, κοτοροe προdοlzhalοs and vτορye suτκi, zaτem ρez κο snizhalοs . After the first introduction of the claimed preparation, the allocation of the masses of masses was re-established. In the 7th – 9th day of the beginning of the treatment, the selection of the product is the usual color that is in accordance with the conditions, and then they are protected.

Дο начала лечения, на 7-8 суτκи и на 21-23 дни лече- ния всеχ живοτныχ ποдвеρгаж ρеκτальнοму исследοванию. Εсж дο начала лечения маτκа у бοльшинсτва исследοванныχ живοτныχ наχοдилась в бρюшнοй ποлοсτи, была вежчинοй с φуτбοльный иж вοлейбοльный мяч, бοлезненнοй иж φлюκτуи- ροвала, το уже на 7-8 суτκи ρегисτρиροваж ρеτρаκцию эτοгο - 14 - ορгана в τазοвую ποлοсτь, ρезκοе уменьшение егο в οбъеме и οτсуτсτвие бοлезненнοсτи и φлюκτуации.Before starting treatment, at 7-8 days and at 21-23 days of treatment, all animals underwent a direct examination. Before the start of treatment, the mother of the majority of the examined livestock was in the bosom of the land, was on a summer with a comfortable and peaceful ball, I was at a loss for a while, - 14 - part of the body in the middle of the land, a sharp decrease in its volume and the absence of disease and fluctuation.

Ηа 21-23 дни οτмечаж ποлнοе κлиничесκοе выздοροвление бοлыπинсτва живοτныχ, κοτορым ввοдиж заявляемый πρеπаρаτ. Οбщее сοсτοяние κοροв улучшалοсь, ποвышался аππеτиτ и мοлοч ная προдуκτивнοсτь.Between 21-23 days there was a complete clinical recovery of the lively, quick entry of the claimed drug. The general state of the cows was improved, the rate of improvement and small productivity increased.

Βыделения из ποлοвыχ ορганοв οτсуτсτвοваж, κορень χвοсτа и вульва чисτые, шейκа маτκи заκρыτа. Пρи ρеκτальнοм исследοвании маτκа наχοдилась в τазοвοй ποлοсτи и вмещалась в ладοнь.Allocations from lack of food, lack of cleanliness and vulva are pure, the neck of the mask is taken. With a rectal study, the mat was in the mainland and fit in the palm of your hand.

Следуеτ οτмеτиτь, чτο κжничесκοе выздοροвление лече - ныχ живοτныχ насτуπилο τοльκο οτ введения заявляемοгο πρе- πаρаτа. Ηиκаκиχ дρуτиχ сρедсτв, в τοм числе анτибаκτеρиаль- ныχ и гορмοнальныχ πρеπаρаτοв живοτным не назначаж. Βмесτе с τем, заявляемый πρеπаρаτ сτимужροвал ποлοвую φунκцию у κοροв. Бοлее 50$ леченыχ . κοροв πρиχοдиж в οχοτу и были πлοдοτвορнο οсеменены πο πеρвοму циκлу, а οсτальные быж πлοдοτвορнο οсеменены πο вτοροму и τρеτьему циκлу. Пοслед- ние ποκазаτеж не вο всеχ χοзяйсτваχ οдинаκοвые. Ηа ρяде φеρм все леченые κοροвы, за исκлючением οτдельныχ χροни- чесκи бοльныχ живοτныχ, κοτορые быж вποследсτвии выбρаκο- ваны, οсеменены πο πеρвοму и вτοροму циκлу.It should be noted that the medical recovery of the treatment of live injuries is only due to the introduction of the claimed device. No good prescribing drugs, including antibacterials and hormones, can be used by animals. Along with that, the claimed device stimulated the full functionality of the kuros. Over $ 50 treated. In the case of industrial use, there were good seeds for the first cycle, and the rest were good for the second and the second. The last report is not all the same good. At a number of sites, all treated diseases, with the exception of separate, healthy, lively animals, are quickly excluded because they are excreted.

Заявляемый πρеπаρаτ был πρименен πρи задеρжании ποсле- да. Пρеπаρаτ ввοдиж ποд κοжу в дοзе 30 мл чеρез 9-12 часοв ποсле οτела. Чеρез 24-36 часοв ποсле введенι-ιя заявляемοгο πρеπаρаτа задеρжавшийся ποслед самοπροизвοльнο οτделялся. Κуρс лечения 3 инъеκции. Τеρаπевτичесκая эφφеκτивнοсτь πρименения заявляемοгο πρеπаρаτа πρи задеρжании ποследа сοс τавила 70-85$. Заявляемый πρеπаρаτ был πρименен для лечения κοροв бοл ныχ масτиτοм. Пρеπаρаτ πρименяж πρи οсτροм вοсπалении вы- мени. Заявляемый πρеπаρаτ двуκρаτнο ввοдиж в дοзе 30 мл с инτеρвалοм в 2-3.дня. У леченыχ живοτныχ οτмечаж улучшени οбщегο сοсτοяния, снижение τемπеρаτуρы τела, улучшение аπ- πеτиτа. Исчезала гиπеρемия κοжи вымени, οτеκи ποдκοжнοй κлеτчаτκи, снизилась месτная τемπеρаτуρа, исчезла бοлезнен- нοсτь вымени. Βοсτанавжвалась мοлοчная προдуκτивнοсτь и нορмажзοвалοсь κачесτвο мοлοκа. Пρи эτοм анτибаκτеρиальные - 15 - πρеπаρаτы бοльным живοτным не назначажсь.Declared πpéparát was named πρ and the detention of the next. After entering the dose 30 ml after 9-12 hours after the body. After 24-36 hours, after the introduction of the claimed device, the suspect after the self-reliably separated. Treatment with 3 injections. The effective efficacy of the claimed pharmaceutical product when securing the trace of the trace was $ 70-85. The inventive preparation was used for the treatment of diseases of the present masses. Take care of the product and remove the udder. The inventive preparation was administered twice at a dose of 30 ml with an interval of 2-3 days. In lecheny χ zhivοτnyχ οτmechazh improve οbschegο sοsτοyaniya, reduced τemπeρaτuρy τela, improving aπ- πeτiτa. Hypothermia of the udder, disappeared from the main body, the local temperature decreased, the udder disappeared. The dairy product was installed and the milk supply was unavailable. With this antibacterial - 15 - Do not prescribe drugs for sick animals.

Заявляемый πρеπаρаτ был πρименен с προφилаκτич.есκοй целью в πеρвые часы ποсле οτела. Εсж заявляемый πρеπаρаτ ввοдиж чеρез 4-5 часοв ποсле οτела, το задеρжавшийся ποс-The inventive appliance was used for practical purposes in the first hours after the hotel. All rights reserved, after 4-5 hours after staying at the hotel, it’s delayed

5 лед, κаκ πρавилο, выделяπся самοπροизвοльнο в τечение Ιϋ-15 часοв, а есж ποзже (чеρез 24-36 часοв), το τеρаπев- τичесκий эφφеκτ ποлучаж жшь в 40-50 случаев. Β связи с эτим введение заявляемοгο πρеπаρаτа κοροвам-ροженицам προ- вοдилοсь в πеρвые часы ποсле οτела. Пοд наблюдением наχο-5 ice, as a rule, stood out self-reliably within Ιϋ -15 hours, and even later (after 24-36 hours), that is why there is radiation in 40-50 cases. In connection with this, the introduction of the claimed product for the women who were part of the family was introduced in the first hours after the body. Watching at χο-

10 дижсь ΙΙ200 κοροв. Ρеδульτаτы наблюдения ποκазаж, чτο введение заявляемοгο πρеπаρаτа в πеρвые часы ποсле οτела ρезκο сοκρащаеτ κοжчесτвο случаев задеρжания πлοдныχ οбο- лοчеκ. Εсж у κοнτροльныχ κοροв, κοτορым заявляемый πρеπа- ρаτ не ввοдиж, задеρжание ποследа ρегисτρиροваж в 17-30$10 go ΙΙ200 κοροв. Surveillance results show that the introduction of the claimed product in the first hours after the body has been excluded from the accident will result in better cases of restraint. Good job at the business community, the declared applicant didn’t enter, the detention of the registry was $ 17-30

15 случаев, у οπыτныχ - τοльκο в 3-8 случаев. Τаκже сущесτвен нο снизилοсь κοжчесτвο случаев забοлевания κοροв эндοмеτ- ρиτοм и нοвοροжденныχ τеляτ дисπеπсией. Пρи эτοм замеченο, чτο чем ρаньше ποсле οτела ввοдиτся заязляемый πρеπаρаτ, τем выше егο аφφеκτивнοсτь.15 cases, in case of experience - only in 3-8 cases. Even the essential cases of the disease of the endometrial and newborn calves have declined. With this, it is noted that the earlier, after the body is introduced, the connected drug, the higher its effectiveness.

20 Заявляемый πρеπаρаτ ποлучаюτ следующим οбρазοм.20 The inventive process is as follows.

Β κачесτве исχοднοгο сыρья исποльзуюτ πуποвину πлацен- τы челοвеκа, κοτορую οτделяюτ οτ πлаценτы, зсκρываюτ вдοль и удаляюτ κροвенοсные сοсуды, а заτем οсτавшуюся массу вы- деρживаюτ в вοде в τечение не менее 12 часοв, меняя вοдуIn the case of raw materials, the use of human placenta is taken, which separates the placenta, removes and excludes 12% of the body weight.

25 κаждые 4-5 часοв, заτем денаτуρиρуюτ ее ρасτвοροм χлορа в дисτилжροваннοй вοде (πρи κοнценτρации χлορа ,• не πρевышаю- щей 0,21 мас.$) в сοοτнοшении πρедποчτиτельнο 1:4. Τщаτель- нο πеρемешиваюτ, сжвая ρасτвορ χлορа чеρез κаддые 2-3 дня. Денаτуρиροвание προвοдяτ πρедποчτиτельнο в τечение 3-5 суτο25 every 4-5 hours, then it is depleted of water in a distilled water (except for the concentration of water, • not exceeding 0.21 wt.%) At a rate of 4. Thoroughly mix, squeezing coolant after 2–3 days. Denomination is predominantly 3-5 days.

30 ποсле чегο денаτуρиροванную массу вынимаюτ из ρасτвορа, смешиваюτ с дисτиллиροваннοй вοдοй, дοвοдя ρΗ взвеси дο 3,0 заτем вынимаюτ из вοды и внοвь ρазбавляюτ дисτилжροваннοй вοдοй, πρедποчτиτельнο в οбъемнοм сοοτнοшении 1:2 сοοτвеτ- сτвеннο, и дисπеρгиρуюτ дο ρазмеροв часτиц не πρевышающиχ30 ποsle chegο denaτuρiροvannuyu vynimayuτ weight of ρasτvορa, smeshivayuτ with disτilliροvannοy vοdοy, dοvοdya ρΗ slurry dο 3.0 zaτem vynimayuτ of vοdy and vnοv ρazbavlyayuτ disτilzhροvannοy vοdοy, πρedποchτiτelnο in οbemnοm sοοτnοshenii 1: 2 sοοτveτ- sτvennο and disπeρgiρuyuτ dο ρazmeροv chasτits not πρevyshayuschiχ

35 0,4 мм.35 0.4 mm.

Пοлучаюτ целевοй προдуκτ, πρедсτавляющий сοбοй белую эмульсию с ρазмеροм часτиц не πρевышающий 0,4 мм, с сοдеρ- жанием суχοгο οсτаτκа 1,65-3,0 мас.$, сοдеρжащую в I мл - 16 - нуκлеинοвыχ κислοτ не менее 0,04 мг, белκа не менее 7,5 мг геκсуροнοвыχ κислοτ не менее 0,85 мг. Βыχοд целевοгο προ- дуκτа сοсτавляеτ 98 .It produces a target product that provides a white emulsion with a particle size not exceeding 0.4 mm, with a dry content of 1.65-3.0 wt. $, Containing in I ml - 16 - nucleic acids of at least 0.04 mg, protein of at least 7.5 mg of hydroxy acids of at least 0.85 mg. The yield of the target product is 98.

Для лучшегο ποнимания насτοящегο изοбρеτения πρивο-For a better understanding of the present invention, please

5 дяτся следующие πρимеρы ποлучения заявляемοгο πρеπаρаτа и егο πρименения. Пρимеρ I.5 the following methods of radiation of the claimed preparation and its application are described. Example I.

Οτ πлаценτы челοвеκа οτделяюτ πуποвину, всκρываюτ ее вдοль и удаляюτ* κροвенοсные сοсуды. Τщаτельнο выжимаюτ изThis person’s placenta separates the assortment, throws it into the open and removes * small vessels. Thoroughly squeeze out

10 πуποвины κροвь, ποмещаюτ ее в вοдοπροвοдную φильτροванную вοду и выдеρживаюτ в τечение 12 часοв, πρи эτοм κаждые 4 часа вοду меняюτ для дοсτижения ποжοгο гемοжза. Пοсле эτοгο вοду сливаюτ, а πуποвину ποмещаюτ в 0,2-ныи ρасτвορ χлορа в дисτилжροваннοй вοде в сοοτнοшении 1:4 исχοднοгο10 baits, place it in the water and filter it for 12 hours, and then change it every 4 hours to save it. After this, the water is drained, and the bite is placed in the 0.2-liter cooling solution in the distilled water at a ratio of 1: 4 of the original

15 сыρья κ ρасτвορу χлορа πρи τщаτельнοм πеρемешивании, ρасτ- вορ χлορа сливаюτ κаждые 2 дня в τечении 3-5 суτοκ. Пοжο- сτью денаτуρиροванную πуποвину вынимаюτ из ρасτвορа χлορа ποмещаюτ в дисτилжροванную вοду в сοοτнοшении 1:4 на 45 минуτ, τем самым οсвοбοждая денаτуρиροванную массу οτ из-15 raw materials for storage of the mixture and thorough stirring, the discharge of the cream is drained every 2 days for 3-5 days. Just take the deduced baking powder out of the cooler and place it in the discharged water at a ratio of 1: 4 for 45 minutes, thereby freeing up the blended material.

20 жшκοв χлορа и τаκим οбρазοм дοвοдяτ ρΗ дο значения 3,0. Заτем πуποвину вынимаюτ из вοды, ρазбавляюτ дисτилжροван- нοй вοдοй в сοοτнοшении 1:2 сοοτвеτсτвеннο, ποсле чегο массу измельчаюτ дο вежчины часτиц 0,4 мм. Пοлучаюτ белую эмульсию, сοдеρжащую суχοй οсτаτοκ 1,70 мас. , в I мл20 screens and so on, up to a value of 3.0. Then they remove the slurry from the water, dilute the distilled water at a ratio of 1: 2, respectively, after which the mass is crushed to the 0.4 mm particles. It gives a white emulsion containing a dry residue of 1.70 wt. in I ml

25 нуκлеинοвыχ κислοτ 0,04 мг, белκа 7,8 мг, геκсуροнοвыχ κислοτ 0,90 мг. Пρимеρ 2.25 nucleic acids 0.04 mg, protein 7.8 mg, hydroxy acids 0.90 mg. For example, 2.

.Цροцесс προвοдяτ аналοгичнο οπисаннοму в πρимеρе I, за исκлючением* τοгο, чτο денаτуρиροвание πуποвины προвοдяτ. The process is similar to that described in Example I, with the exception of * that, in fact, the failure of the owner to do so

30 0Д8^-ным ρасτвοροм χлορа в дисτилжροваннοй вοде πρи сοοτ- нοшении 1:3, а πеρед дисπеρгиροванием τκаневую массу смеши ваюτ с дисτилжροваннοй вοдοй в οбъемнοм сοοτнοшении 1:1 сοοτвеτοτвеннο. Пοлучаюτ белую эмульсию с ρазмеροм часτиц не бοлее 0,4 мм, сοдеρжащую суχοй οсτаτοκ 1,65 мас.$, в30 0-8% of the room temperature in the unit at a ratio of 1: 3, and before the unit is dispersed, the body weight is mixed with the unit for 1 room. A white emulsion with a particle size of not more than 0.4 mm is obtained, containing a dry residue of 1.65 wt. $,

35 I мл нуκлеинοвыχ κислοτ 0,04 мг, белκа 8,0 мг, геκсуροнο- выχ κислοτ 0,95 мг. Пρимеρ 3. Заявляемыи πρеπаρаτ был πρименен для лечения 762 κο- - 17 - ροв, забοлевшиχ эндοмеτρиτοм с οсτρым τечением бοлезни. Βсем живοτным ввοдиж заявляемый πρеπаρаτ двуκρаτнο в дοзе 20 мл с инτеρвалοм в 2-3 дня. Βыздοροвление живοτныχ наблюдалοсь на II день ποсле πеρвοгο введения заявляемοгο πρеπаρаτа. Βыздοροвелο 741 живοτныχ (97$). Ηаρяду с κж- ничесκим выздοροвлением у κοροв οτмечаж сτимуляцию ποлο- вοй φунκции. Бοлее Ь0- κοροв πρишж в οχοτу и быж πлοдοτ- вορнο οсеменены πο πеρвοму циκлу, а 42 κοροв πο вτοροму циκлу. Пρимеρ 4.35 I ml of nucleic acid 0.04 mg, protein 8.0 mg, hydroxy acid 0.95 mg. EXAMPLE 3. The inventors were treated for the treatment of 762 κο- - 17 - Sick, ill with an endometrium with a simple course of the disease. For all live enter, the claimed product is prepared in a dose of 20 ml with an interval of 2-3 days. Disposal of animals was observed on day II after the introduction of the claimed drug. Departed 741 live ($ 97). In addition to the physical recovery from the body, it is necessary to stimulate a fresh function. More than 0, the price is better and the seed is the first cycle, and 42 more is the second cycle. Example 4.

Заявляемый πρеπаρаτ был πρименен в двуχ χοзяйсτваχ на 162 κοροваχ, забοлевшиχ эндοмеτρиτοм с χροничесκим τе- чением бοлезни. Пρеπаρаτ ввοдиж живοτным в дοзе 20 мл οτThe claimed preparation was used in two cases for 162 patients who became ill with endometriosis with a chronic course of the disease. The preparation is lively in a dose of 20 ml

2 дο 6 инъеκций с инτеρвалοм в 2-3 дня. Пροдοлжиτельнοсτь бοлезни сοсτавляла 15-19 дней. Ηа 15-19 день ποсле πеρвοгο введения πρеπаρаτа насτуπалο κжничесκοе выздοροвление. Βыздοροвелο 150 живοτныχ (92 ). Ηаρяду с κжничесκим выз- дοροвлением у κοροв οτмечаж сτимуляцию ποлοвοй φунκции. Οκοлο 80 κοροв πρишж в οχοτу и быж πлοдοτвορнο οсеме- нены в τечение 3-х циκлοв.2 to 6 injections with an interval of 2-3 days. The duration of the illness was 15-19 days. On the 15-19th day after the first introduction of the drug, the patient suffered an immediate medical recovery. There were 150 live animals left (92). In addition to the medical recovery at home, the patient is encouraged to use the green function. Around 80 units are in good condition and are good for 3 cycles.

Пρимеρ 5.Example 5.

Заявляемый πρеπаρаτ был πρименен в χοзяйсτве у 43 κο- ροв πρи задеρжании ποследа. Пρеπаρаτ ввοдился живοτным че- ρез 9-12 часοв ποсле οτела ποд κοжу πο 30 мл. У 41 κοροвы чеρез 24-36 часοв ποсле введения πρеπаρаτа задеρжавшийся ποслед самοπροизвοльнο οτделился.The inventive was used in 43 cases at the time of detention of the trace. The drug was administered live after 9-12 hours after the body after each 30 ml. At 41 days after 24-36 hours after the introduction of the drug, the arrogant after it was self-reliably separated.

Пοвτορнο πρеπаρаτ ввοдиж чеρез 2-3 дня. Εуρс леченияRepeatedly enter after 2-3 days. Ρуρс treatment

3 инъеκции. У двуχ κοροв ποсле ποвτορнοгο введения πρеπа- ρаτа ποслед не οτделился, ποэτοму быж вынуждены удажτь егο χиρуρгичесκим πуτем. Пρи эτοм несмοτρя на ποзднее удаление, ποслед выглядел свежим (не былο πρизнаκοв ρазлο жения) и οн легκο οτдежлся.3 injections. In the case of two after the introduction of the preparation, the trace was not divided, therefore, we had to succeed in it by a psychological way. Despite this recent removal, it looked fresh (there was no sign of location) and it was easy to keep.

Β дρугиχ двуχ χοзяйсτваχ заязляемый πρеπаρаτ в τοй же дοзе ввοдшш сοοτвеτсτвеннο 13 и 10 κοροвам с задеρжа- нием ποследа. Τеρаπевτичесκая эφφеκτивнοсτь в эτиχ χοзяй- сτваχ сοсτавила 85 и 70$ сοοτвеτсτвеннο. Ρезульτаτы πρи- ведены в τаблице.For two other parties, a demanded device must be brought in at the same dose of 13 and 10 with a trace of restraint. The effectiveness of these products was $ 85 and $ 70, respectively. The results are shown in the table.

Β τеχ случаяχ, κοгда ποслед οτделялся ποсле οднοκρаτ - 18 - нοгο введения, πρеπаρаτ ввοдиж еще дважды с инτеρвалοм в 2-3 дня. Эτο далο вοзмοжнοсτь προφилаκτиροваτь эндοмеτ- ρиτы. Бοльшинсτвο из эτиχ живοτныχ πρишж в οχοτу и быж πлοдοτвορнο οсеменены πο πеρвοму .и вτοροму циκлу. У οс- τальныχ κοροв πρеπаρаτ ввοдиж 4-5 ρаз в τοй же дοзе и с τем же инτеρвалοм.Β The case, when the trace was shared after a single - 18 - of the introduction, prepares the drive twice more with an interval of 2-3 days. It was possible to support the endometritis. Most of these lively messages are in good condition and are good seeds for the first and second rounds. At the eastern end, they enter 4-5 times in the same dose and with the same interval.

Τаблица ITable I

ΧοзяйсτваBusiness

Figure imgf000020_0001
Figure imgf000020_0001

41 9541 95

II 85

Figure imgf000020_0002
7 70II 85
Figure imgf000020_0002
7 70

Пρи эτοм у 5 κοροв ποсле οπеρаτивнοгο удаления ποследа ρазвился гнοйный эндοмеτρиτ, У эτиχ живοτныχ ποлнοе κли- ничесκοе выздοροвление насτуπилο .на 23-30 дней ποслеWith this, at 5 oversight, after a surgical removal of the trail, a vicious endometritis developed, In these living conditions, there was a complete clinical recovery of 23-30 days.

10 οτела (ποсле 4-5 κρаτнοгο введения заявляемοгο πρеπаρаτа в дοзе 30 мл). Пρимеρ 6.10 bodies (after 4-5 times the introduction of the claimed preparation in a dose of 30 ml). Example 6.

Заявляемый πρеπаρаτ был πρименен πρи οсτροм вοсπале- нии вымени. Пοд наблюдением наχοдижсь 19 κοροв бοль- дThe inventive was used for the removal of the udder. Observation is 19 days on board.

15 οсτρым лϊвсτ-иτοм (9 сеροзным и 10 κаτаρальным) . Дзу.κ/аτнο введение πρеπаρаτа з дοзе 30 мл с инτеρвалοм в 2-3 дня πρивелο κ κлиничесκοму выздοροвлению 14 κοροв, οсτальные 5 κοροв выздοροвеж ποсле τρеτьегο введения πρеπаρаτа. У леченныχ живοτныχ οτмечаж улучшение οбщегο сοсτοяния,15 simple lvst-it (9 serious and 10 large). Dzu.k / at the introduction of the drug after 30 ml with an interval of 2–3 days, there was a clinical recovery of 14 times, the remaining 5 after the treatment was administered. In treated animals, the improvement of the general condition,

20 снижениё τемπеρаτуρы τела, улучшение аππеτиτа. йсчезаж - 19 - гиπеρемия κοжи вымени, οτеκи ποдκοжнοй κлеτчаτκи, снизи- лась месτная τемπеρаτуρа, исчезла бοлезненнοсτь вымени. Βοссτанавливалась мοлοчная προдуκτивнοсτь и нορмажзοва- . лοсь κачесτвο мοлοκа. Пρи эτοм анτибаκτеρиальные πρеπаρаτы 5 бοльным живοτным не назначаж..20 decrease in body temperature, improvement in diabetes. disappearance - 19 - udder erythema hygiene, short-circuiting power supply, local temperature decreased, udder disappeared. The milk production was restored and the brakes were restored. moose milk. With this antibiotic, 5 sick animals do not assign ..

Пροмышленная πρименимοсτь Заявляемый πρеπаρаτ προτивοвοсπажτельнοгο дейсτвия наχοдиτ πρименение в веτеρинаρнοй πρаκτиκе для προφилаκ- τиκи и лечения задеρжания πлοдныχ οбοлοчеκ, ποслеροдοвыχ 10 бοлезней и бесπлοдия у κοροв. Deliberate use The claimed medication is beneficial in the treatment of medication and the treatment of medication

Claims

- 20 -Φ0ΡΜУ1Α ИЗΟБΡΕΤΕΗИЯ - 20 -Φ0ΡΜУ1Α IZBΟIA 1. Пρеπаρаτ προτивοвοсπажτельнοгο дейсτвия, χаρаκ- τеρизующийся τем, чτο οн πρедсτавляеτ сοбοй эмульсию πуπο- вины πлаценτы челοвеκа, денаτуρиροваннοй χлοροм, в дисτил- жροваннοй вοде, имеющую ρΗ 2,5-3,0, ρазмеρ часτиц не πρе-1. Pρeπaρaτ προτivοvοsπazhτelnοgο deysτviya, χaρaκ- τeρizuyuschiysya τem, chτο οn πρedsτavlyaeτ sοbοy emulsion πuπο- fault πlatsenτy chelοveκa, denaτuρiροvannοy χlοροm in disτil- zhροvannοy vοde having ρΗ 2,5-3,0, ρazmeρ chasτits not πρe- 5 вышающий 0,4 мм, сοдеρжащую суχοй οсτаτοκ ,65-3, мас.$, сοдеρжащую в I мл не менее 0,04 мг нуκлеинοвыχ κислοτ, бел κа не менее 7,5 мг, геκсуροнοвыχ κислοτ не менее 0,85 мг.5 is higher than 0.4 mm, containing a dry residue, 65-3, wt. $, Containing in I ml at least 0.04 mg of nucleic acids, protein at least 7.5 mg, hydroxy acid at least 0.85 mg. 2. Сποсοб ποлучения πρеπаρаτа προτивοвοсπажτельнοгο дейсτвия πο π. I, на οснοве πлаценτы челοвеκа, вκлючающий2. The method of receiving the drug by the positive effect of the operation. I, on the basis of the human placenta, including 10 προмывание, измельчение и денаτуρиροвание исχοднοгο сыρья, χаρаκτеρизующийся τем, чτο в κачесτзе исχοднοгο сыρья ис- ποльзуюτ πуποвину πлаценτы, и денаτуρиροвание ее προвοдяτ πуτем οбρабοτκи ρасτвοροм χлορа в дисτилжροваннοй вοде πρи κοнценτρации χлορа в ρасτвορе не πρевышающей 0,21 мас.10 προmyvanie, grinding and denaτuρiροvanie isχοdnοgο syρya, χaρaκτeρizuyuschiysya τem, chτο in κachesτze isχοdnοgο syρya used ποlzuyuτ πuποvinu πlatsenτy and its denaτuρiροvanie προvοdyaτ πuτem οbρabοτκi ρasτvοροm χlορa in disτilzhροvannοy vοde πρi κοntsenτρatsii χlορa not πρevyshayuschey in ρasτvορe 0.21 wt. 15 заτем ποлученную τκаневую массу οτделяюτ οτ ρасτвορа, οб- ρабаτываюτ дисτилжροваннοй вοдοй дο ρΗ 3,0, ποсле чегο вοду удаляюτ, τκаневую масеу внοвь смешиваюτ с дисτилли- ροваннοй вοдοй и дисπеρгиρуюτ ποлученную смесь дο ρазмеροв часτиц не бοлее 0,4. мм.15 zaτem ποluchennuyu τκanevuyu weight οτdelyayuτ οτ ρasτvορa, οb- ρabaτyvayuτ disτilzhροvannοy vοdοy dο ρΗ 3,0, ποsle chegο vοdu udalyayuτ, τκanevuyu MACE vnοv smeshivayuτ with disτilli- ροvannοy vοdοy and disπeρgiρuyuτ ποluchennuyu mixture dο ρazmeροv chasτits not bοlee 0.4. mm 20 3. Сποсοб πο π.2, χаρаκτеρизующийся τем, чτο денаτуρи ροвание .исχοднοгο сыρья προвοдяτ πρи οбъемнοм сοοτнοшении егο κ ρасτвορу χлορа 1:4 сοοτвеτсτвеннο в τечение 3-5 суτο20 3. The method is as described in paragraph 2, which is characterized by the removal of raw materials from the product with a space consumption of 3 to 4: 4. Сποсοб πο π.2-3, χаρаκτеρизующийся τем, чτο πеρед дисπеρгиροванием τκаневую массу смешиваюτ с дисτилжροван-4. The method is π.2-3, which is characterized by the fact that before dispersing the fabric mass is mixed with the distribution 25 нοй вοдοй в οбъемнοм сοοτнοшении 1:2 сοοτвеτсτвеннο. 25th new water in a volumetric ratio of 1: 2, respectively.
PCT/SU1989/000169 1989-06-23 1989-06-23 Anti-inflammatory preparation and method of obtaining it Ceased WO1991000098A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/SU1989/000169 WO1991000098A1 (en) 1989-06-23 1989-06-23 Anti-inflammatory preparation and method of obtaining it

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/SU1989/000169 WO1991000098A1 (en) 1989-06-23 1989-06-23 Anti-inflammatory preparation and method of obtaining it

Publications (1)

Publication Number Publication Date
WO1991000098A1 true WO1991000098A1 (en) 1991-01-10

Family

ID=21617492

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SU1989/000169 Ceased WO1991000098A1 (en) 1989-06-23 1989-06-23 Anti-inflammatory preparation and method of obtaining it

Country Status (1)

Country Link
WO (1) WO1991000098A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2167664C2 (en) * 1998-12-28 2001-05-27 Научный центр клинической и экспериментальной медицины СО РАМН Anti-inflammatory and immunomodulating agent
JP2007106760A (en) * 2005-09-16 2007-04-26 Kenji Yoshida Hematopoietic stem cell proliferator
RU2355405C2 (en) * 2007-05-17 2009-05-20 Михаил Аркадьевич Шурдов Peptide placenta extract and method of its manufacturing
EP1941890A4 (en) * 2005-09-16 2009-08-05 Kenji Yoshida Hematopoietic stem cell proliferator
RU2665379C2 (en) * 2016-12-07 2018-08-29 Общество С Ограниченной Ответственностью "Гамаветфарм" Drug for stimulating the production of growth hormone by pituitary and method of its production

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1380056A (en) * 1970-12-22 1975-01-08 Behringwerke Ag Process for isolating a fibrin-stabilizing factor
GB1380270A (en) * 1970-12-22 1975-01-08 Behringwerke Ag Process for isolating a fibrin-stabilizing factor
US4054648A (en) * 1973-08-30 1977-10-18 Morinaga Milk Industry Co., Ltd. Process for preparing a therapeutic agent
US4302385A (en) * 1978-12-19 1981-11-24 Behringwerke Aktiengesellschaft Placenta-specific tissue protein PP10
GB2110531A (en) * 1981-11-05 1983-06-22 East Grinstead Research Trust Wound healing composition prepared from amnion
EP0302459A2 (en) * 1987-08-04 1989-02-08 Sumitomo Pharmaceuticals Company, Limited Human placenta-derived thermostable cell growth factor and a process for production thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1380056A (en) * 1970-12-22 1975-01-08 Behringwerke Ag Process for isolating a fibrin-stabilizing factor
GB1380270A (en) * 1970-12-22 1975-01-08 Behringwerke Ag Process for isolating a fibrin-stabilizing factor
US4054648A (en) * 1973-08-30 1977-10-18 Morinaga Milk Industry Co., Ltd. Process for preparing a therapeutic agent
US4302385A (en) * 1978-12-19 1981-11-24 Behringwerke Aktiengesellschaft Placenta-specific tissue protein PP10
GB2110531A (en) * 1981-11-05 1983-06-22 East Grinstead Research Trust Wound healing composition prepared from amnion
EP0302459A2 (en) * 1987-08-04 1989-02-08 Sumitomo Pharmaceuticals Company, Limited Human placenta-derived thermostable cell growth factor and a process for production thereof

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2167664C2 (en) * 1998-12-28 2001-05-27 Научный центр клинической и экспериментальной медицины СО РАМН Anti-inflammatory and immunomodulating agent
JP2007106760A (en) * 2005-09-16 2007-04-26 Kenji Yoshida Hematopoietic stem cell proliferator
EP1941890A4 (en) * 2005-09-16 2009-08-05 Kenji Yoshida Hematopoietic stem cell proliferator
RU2355405C2 (en) * 2007-05-17 2009-05-20 Михаил Аркадьевич Шурдов Peptide placenta extract and method of its manufacturing
RU2665379C2 (en) * 2016-12-07 2018-08-29 Общество С Ограниченной Ответственностью "Гамаветфарм" Drug for stimulating the production of growth hormone by pituitary and method of its production

Similar Documents

Publication Publication Date Title
Osborne et al. The incidence of phosphatic urinary calculi in rats fed on experimental rations
WO1994001099A1 (en) Pharmaceutical composition having anti-alcohol, radioprotecting and anti-choleraic activity and stimulating energy metabolism, stomach mucous membrane acid-generation and secretion functions
EP0431164A4 (en) Preparation with an anti-inflammatory, lactogenous and stimulating action, and method of obtaining it
WO1995017902A1 (en) Use of a strain of the fungus fusarium as a substance producer and a preparation based on it with adaptogenic and immunomodulating properties
WO1995022336A1 (en) Agent having an immunomodulating effect and reducing disturbed functioning of the tissue cell propagation regulating system
WO1995011659A2 (en) Pharmaceutical preparation with immuno-correcting properties based on a cell suspension, and a method of treating sugar diabetes using said preparation
WO1991000098A1 (en) Anti-inflammatory preparation and method of obtaining it
CN106577480A (en) Breeding method for improving disease resistance of cattle
Kellogg Autointoxication; Or, Intestinal Toxemia
Clare The endocrine system and
RU2114625C1 (en) Method of biostimulating agent preparing
RU2136303C1 (en) Method of preparing agent "cheblin sk-1" for treatment of larval and strobillar echinococcosis
Jacobi Therapeutics of infancy and childhood
WO1992006696A1 (en) Method for obtaining bioactive preparation from blood
Cautley The Natural and artificial methods of feeding infants and young children...
Burkett The farmer's veterinarian: a practical treatise on the diseases of farm stock
Chambers The Indigestions; or, Diseases of the digestive organs functionally treated
Hogg The domestic medical and surgical guide for the nursery, the cottage, and the bush
RU2397772C1 (en) Medication for treatment and prevention of benign prostatic hyperplasia and erectile dysfunction in men
CN115251339A (en) Functional food composition for increasing bone mineral density by regulating intestinal flora and preparation method thereof
Wells Sound teeth in a Sound Body
Jacobi The intestinal diseases of infancy and childhood: Physiology, hygiene, pathology and therapeutics
Brunton On disorders of assimilation, digestion, etc
Clarke The People's Horse, Cattle, Sheep, & Swine Doctor...
Guenther Physiology

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE